AU2115801A

AU2115801A - P15paf cell cycle proteins associated with pcna, compositions and methods of use

Info

Publication number: AU2115801A
Application number: AU21158/01A
Authority: AU
Inventors: Betty Huang; Ying Luo; Peiwen Yu
Original assignee: Rigel Pharmaceuticals Inc
Current assignee: Rigel Pharmaceuticals Inc
Priority date: 1999-10-18
Filing date: 2000-10-18
Publication date: 2001-04-30
Also published as: EP1224470A2; CA2387731A1; WO2001029072A9; WO2001029072A3; JP2003513231A; WO2001029072A2

Description

WO 01/29072 PCT/USOO/41296

P

15 PAF CELL CYCLE PROTEINS ASSOCIATED WITH PCNA, COMPOSITIONS AND METHODS OF USE FIELD OF THE INVENTION The present invention is directed to compositions involved in cell cycle regulation and methods of 5 use. More particularly, the present invention is directed to genes encoding pl 5 PAF proteins and p1 5 PAF proteins involved in cell cycle regulation. Methods of use include use in assays screening for modulators of the cell cycle and use as therapeutics. BACKGROUND OF THE INVENTION Cells cycle through various stages of growth, starting with the M phase, where mitosis and 10 cytoplasmic division (cytokinesis) occurs. The M phase is followed by the G1 phase, in which the cells resume a high rate of biosynthesis and growth. The S phase begins with DNA synthesis, and ends when the DNA content of the nucleus has doubled. The cell then enters G2 phase, which ends when mitosis starts, signaled by the appearance of condensed chromosomes. Terminally differentiated cells are arrested in the G1 phase, and no longer undergo cell division. 15 The hallmark of a malignant cell is uncontrolled proliferation. This phenotype is acquired through the accumulation of gene mutations, the majority of which promote passage through the cell cycle. Cancer cells ignore growth regulatory signals and remain committed to cell division. Classic oncogenes, such as ras, lead to inappropriate transition from G1 to S phase of the cell cycle, mimicking proliferative extracellular signals. Cell cycle checkpoint controls ensure faithful 20 replication and segregation of the genome. The loss of cell cycle checkpoint control results in genomic instability, greatly accelerating the accumulation of mutations which drive malignant transformation. Thus, modulating cell cycle checkpoint pathways and other such pathways with therapeutic agents could exploit the differences between normal and tumor cells, both improving the selectivity of radio- and chemotherapy, and leading to novel cancer treatments. As another 25 example, it would be useful to control entry into apoptosis. 1 WO 01/29072 PCT/USOO/41296 On the other hand, it is also sometimes desirable to enhance proliferation of cells in a controlled manner. For example, proliferation of cells is useful in wound healing and where growth of tissue is desirable. Thus, identifying modulators which promote, enhance or deter the inhibition of proliferation is desirable. Of note, while general discovery of compounds is always being explored, 5 unfortunately, many compounds do not have known functions, see, for example, Nagase, et al., DNA Res., 2(1):37-43 (1995). The proliferating cell nuclear antigen, PCNA, is an auxiliary factor for DNA polymerase processivity. PCNA interacts with numerous DNA replication/repair enzymes, such as DNA polymerase delta and epsilon, replication factor C (RF-C p140), DNA ligase 1, replication 10 endonuclease FEN-1, Uracil-DNA glycosylase 2, MLH1, MSH2, and the DNA repair endonuclease, XPG. (Chuang et al., (1997). Science, 277, 1996-2000; Loor et al.,(1997). Nucleic Acids Res., 25, 5041-5046; Umar et al, (1996). Cell, 87, 65-73). Most of these enzymes do not recognize DNA sequences with high specificity. PCNA binds to double strand DNA as a homotrimer and serves as a platform to tether polymerases to the DNA template during DNA synthesis (Kelman et al, (1998). 15 Trends Biochem. Sci., 23, 236-238). PCNA has been shown to interact with DNA (cytosine-5) methyltransferase (MCMT) in post-replication DNA synthesis. MCMT methylation of newly synthesized DNA regulates chromatin organization and gene expression. Several non-enzymatic cell cycle regulators, such as CDK inhibitors p 21 CIP/WAF1 (Xiong et al,(1992) Cell, 71, 505-514; Flores-Rozas et al, (1994). Proc. NatI. Acad. Sci. USA, 91, 8655-8659; Waga et 20 al., (1994), Nature, 369, 574-578), p57Kip 2 (Watanabe et al, (1998). Proc. NatI. Acad. Sci. U. S. A., 95, 1392-1397), and Gadd45 (Smith et al, (1994). Science, 266, 1376-1380; Hall et al, (1995). Oncogene, 10, 2427-2433; Sanchez et al., (1995). Bioessays, 17, 545-548), also bind to PCNA. p21 and p57 both contain two separate binding activities: a CDK-cyclin binding domain at the N terminus and a C-terminally located PCNA binding site (Watanabe et al., supra; Luo et al., (1995). 25 Nature, 375, 159-161; Nakanishi et al, (1995). J. Biol. Chem., 270, 17060-17063), both of which are capable of inhibiting cell cycle progression. Mutagenesis and p21-PCNA crystal structure analysis have identified short amino acid motif (1 4 4 QTSMTDFY151 in human p21 and 26 8

SGPLISDFF

2 76 in human p57) critical for binding to PCNA. In particular, the hydrophobic Met/Leu and Phe residue (underlined), are required for p21 and p57 to bind PCNA at high affinities 30 (Watanabe et al., supra; Warbrick et al., (1995). Current Biology, 5, 275-282; Gulbis et al., (1996). Cell, 87, 297-306). In addition to these two CDK inhibitors, a similar conserved PCNA binding motif (also named PIP-box ) containing QXXL/I/MXXF/Y (Warbrick, 1998, supra), is also found in several other PCNA interacting proteins, including xeroderma pigmentosum group G [XPG, (Ludwig et al., (1997). J. Biol. Chem., 272, 24522-24529)], flap endonuclease [FEN-1 (Li et al.,(1995). J. Biol. 35 Chem., 270, 22109-22112)], and DNA-(cytosine-5) methyltransferase [MCMT, (Chuang et al., supra 1997)]. The p21-PCNA association does not affect the overall structure of PCNA or the PCNA-DNA association (Gulbis et al., 1996 supra). Instead, p21 is capable of competing with these PCNA-binding proteins, potentially preventing PCNA from binding to DNA polymerase and 2 WO 01/29072 PCT/USOO/41296 other replication factors. Despite the desirability of identifying cell cycle components and modulators, there is a deficit in the field of such compounds. Accordingly, it would be advantageous to provide compositions and methods useful in screening for modulators of the cell cycle. It would also be advantageous to 5 provide novel compositions which are involved in the cell cycle. SUMMARY OF THE INVENTION The present invention provides p1 5 PAF cell cycle proteins and nucleic acids which encode such proteins. 10 Also provided are methods for screening for a bioactive agent capable of modulating the cell cycle. The method comprises combining a p1 5 PAF cell cycle protein and a candidate bioactive agent and a cell or a population of cells, and determining the effect on the cell in the presence and absence of the candidate agent. Therapeutics for regulating or modulating the cell cycle are also provided. In one aspect, a recombinant nucleic acid encoding a p1 5 PAF cell cycle protein of the present 15 invention comprises a nucleic acid that hybridizes under high stringency conditions to a sequence complementary to that set forth in Figure 1 or to the Figure 1 sequence itself. In a preferred embodiment, the p1 5 PAF cell cycle protein provided herein binds to proliferating cell nuclear antigen (PCNA). In one embodiment, a recombinant nucleic acid is provided which comprises a nucleic acid 20 sequence as set forth in Figure 1 or its complement. In another embodiment, a recombinant nucleic acid encoding a p1 5 PAF cell cycle protein is provided which comprises a nucleic acid sequence having at least 85% sequence identity to a sequence as set forth in Figure 1 or its complement. In a further embodiment, provided herein is a recombinant nucleic acid encoding an amino acid sequence as depicted in Figure 2A. 25 In another aspect of the invention, expression vectors are provided. The expression vectors comprise one or more of the recombinant nucleic acids provided herein operably linked to regulatory sequences recognized by a host cell transformed with the nucleic acid. Further provided herein are host cells comprising the vectors and recombinant nucleic acids provided herein. Moreover, provided herein are processes for producing a p 15 PAF cell cycle protein comprising 30 culturing a host cell as described herein under conditions suitable for expression of the p1 5 PAF cell cycle protein. In one embodiment, the process includes recovering the pl 5 PAF cell cycle protein. Also provided herein are recombinant p1 5 PAF cell cycle proteins encoded by the nucleic acids of the present invention. In one aspect, a recombinant polypeptide is provided herein which 3 WO 01/29072 PCT/USOO/41296 comprises an amino acid sequence having at least 80% sequence identity with a sequence as set forth in Figure 2A. In one embodiment, a recombinant p1 5 PAF cell cycle protein is provided which comprises an amino acid sequence as set forth in Figure 2A. In another aspect, the present invention provides isolated polypeptides which specifically bind to a 5 p1 5 PAF cell cycle protein as described herein. Examples of such isolated polypeptides include antibodies. Such an antibody can be a monoclonal antibody. In one embodiment, such an antibody reduces or eliminates the biological function of said p1 5 PAF cell cycle protein. Further provided herein are methods for screening for a bioactive agent capable of binding to a p1 5 PAF cell cycle protein. In one embodiment the method comprises combining a pl 5 PAF cell cycle 10 protein and a candidate bioactive agent, and determining the binding of said candidate bioactive agent to said p1 5 PAF cell cycle protein. In another aspect, provided herein is a method for screening for a bioactive agent capable of interfering with the binding of a p 15 PAF cell cycle protein and a PCNA protein. In one embodiment, such a method comprises combining a p15PAF cell cycle protein, a candidate bioactive agent and a 15 PCNA protein, and determining the binding of the p1 5 PAF cell cycle protein and the PCNA protein. If desired, the p1 5 PAF cell cycle protein and the PCNA protein can be combined first. In addition, the assay may comprise p21 as a competitor of p1 5 PAF binding to PCNA. Further provided herein are methods for screening for a bioactive agent capable of modulating the activity of p1 5 PAF cell cycle protein. In one embodiment the method comprises adding a candidate 20 bioactive agent to a cell comprising a recombinant nucleic acid encoding a p1 5 PAF cell cycle protein, and determining the effect of the candidate bioactive agent on the cell. In a preferred embodiment, a library of candidate bioactive agents is added to a plurality of cells comprising a recombinant nucleic acid encoding a pl 5 PAF cell cycle protein. Other aspects of the invention will become apparent to the skilled artisan by the following 25 description of the invention. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 show the nucleic acid sequence of SEQ ID NO:1, which includes sequence encoding a p1 5 PAF cell cycle protein. Figure 2A and 2B show amino acid sequences. Figure 2A shows the amino acid sequence of SEQ 30 ID NO:2, a cell cycle protein termed herein R0101 or p5P'af, wherein the terms R0101 and p15Paf are used herein interchangeably, and wherein a PCNA-binding motif is in bold. Figure 2B shows an alignment wherein a conserved PCNA-binding motif is in bold for a variety of proteins. 4 WO 01/29072 PCT/USOO/41296 Figure 3 shows p1 5"f expression in different tissues. Figure 4 shows that p 15 PAF is localized in the nucleus. Figure 5 shows that p1 5 PAF expression is elevated in tumor tissues. Figure 6 shows that p1 5 paf competes with p21 to bind to PCNA. 5 Figure 7 shows the results using wild type p15paT and p15Pa

T

M1/2. Figure 8 shows the results of yeast 2-hybrid assays. Figure 9 shows a drawing, which without being bound by theory, shows a proposed binding model for p 1 5 PAF DETAILED DESCRIPTION OF THE INVENTION 10 The present invention provides pl 5 PAF cell cycle proteins and nucleic acids which encode such proteins. Also provided are methods for screening for a bioactive agent capable of modulating the cell cycle. The method comprises combining a p15PAF cell cycle protein and a candidate bioactive agent and a cell or a population of cells, and determining the effect on the cell in the presence and absence of the candidate agent. Other screening assays including binding assays are also 15 provided herein as described below. Therapeutics for regulating or modulating the cell cycle are also provided and described herein. Diagnostics, as further described below, are also provided herein. A p1 5 PAF cell cycle protein of the present invention may be identified in several ways. "Protein" in this sense includes proteins, polypeptides, and peptides. A p1 5 PAF cell cycle protein may be 20 initially identified by its association with a protein known to be involved in the cell cycle. In one embodiment provided herein, a pl 5 PAF cell cycle protein as defined herein has one or more of the following characteristics: binding to PCNA; competing with p21 for binding to PCNA; homology to FEN1 or p21CIP1; and/or p1 5 PAF cell cycle protein activity as described herein. In preferred embodiments, the p15PAF cell cycle protein is involved in mitosis and the cell cycle. Most 25 preferably, the p1 5 PAF cell cycle protein comprises a PCNA-binding motif selected from the sequences consisting of QGRLDDFF, QTSMTDFY, QTTITSHF, QLRIDSFF and QKGIGEFF. More preferably, the pl 5 PAF cell cycle protein comprises the sequence QKGIGEFF. In another embodiment, the p1 5 PAF cell cycle protein binds to CDK2 and CDK3, preferably at a lower affinity than with PCNA. CDKs have been reported on, see, for example, Chen, I., et al., Oncogene 30 12:595-607 (1996); Chen, J., et al., Nature 374:386-388 (1995); Luo, Y., et al., Nature 375:159-161 5 WO 01/29072 PCT/USOO/41296 (1995); Harper, J., et al., Cell 75:805-816 (1993); Gu, Y., et al., Nature 366:707-710 (1993); Toyoshima, H., et al., Cell 78:67-74 (1994). PCNA is required for both DNA replication and repair. Studies have shown that coordination between cell cycle arrest and DNA repair is linked to the activation of PCNA and PCNA-binding 5 peptides. PCNA interacts with proteins including those involved in cell cycle progression, checkpoint control, DNA replication and repair [Fotedar and Fotedar, Prog. Cell Cycle Res. 1:73-89 (1995); Prosperi, Prog. Cell Cycle Res. 3:193-210 (1997); Kelman and Hurwitz, Trends Biochem. Sci. 23(7):236-8 (1998)]. Observations point to the p53 tumor suppressor protein as a regulator of PCNA expression, which seems to be compatible with the function of p53 as an inducer of DNA 10 repair, and PCNA, as a DNA repair protein [Morris et al., Proc. NatI. Acad. Sci. U.S.A. 93(2):895-9 (1996)]. Moreover, PCNA has been implicated in mismatch repair [Kolodner and Marsischky, Curr. Opin. Genet. Dev. 9(1):89-96 (1999)]. Regarding PCNA, also see, e.g., Warbrick, Bioessays 20(3):195-9 (1998), Warbrick, et al., Oncogene, 14(19):2313-21 (1997); Chen, et al., PNAS USA, 93(21):11597-602 (1996); and Jonsson, et al., EMBO J., 17(8):2412-25 (1998). 15 FEN1 peptides, to which the p15PAF cell cycle protein described herein shares homology, compete with p21CIP1 peptides for binding sites on PCNA. Further regarding FEN1, see, e.g., Hosfield, et al., Cell, 95(1):135-46 (1998). In preferred embodiments, the p1 5 PAF cell cycle proteins and nucleic acids herein have greater homology to R0101 than to FEN1, p21 or other PCNA binding proteins and nucleic acids. In another preferred embodiment, the p 15 PAF cell cycle protein nucleic 20 acid hybridizes specifically to the complement of the sequence shown in Figure 1. In certain embodiment herein, the assays provided herein exclude p21, XPG, MCMT and FEN1. In one embodiment, cell cycle nucleic acids or p 15 PAF cell cycle proteins are initially identified by substantial nucleic acid and/or amino acid sequence identity or similarity to the sequence(s) provided herein. In a preferred embodiment, cell cycle nucleic acids or p1 5 PAF cell cycle proteins 25 have sequence identity or similarity to the sequences provided herein as described below and one or more of the p1 5 PAF cell cycle protein bioactivities as further described below. Such sequence identity or similarity can be based upon the overall nucleic acid or amino acid sequence. In a preferred embodiment, a protein is a "cycle cell protein" as defined herein if the overall sequence identity of the amino acid sequence of Figure 2A is preferably greater than about 75%, 30 more preferably greater than about 80%, even more preferably greater than about 85% and most preferably greater than 90%. In some embodiments the sequence identity will be as high as about 93 to 95 or 98%. In another preferred embodiment, a cycle cell protein has an overall sequence similarity with the amino acid sequence of Figure 2A of greater than about 80%, more preferably greater than about 35 85%, even more preferably greater than about 90% and most preferably greater than 93%. In 6 WO 01/29072 PCT/USOO/41296 some embodiments the sequence identity will be as high as about 95 to 98 or 99%. As is known in the art, a number of different programs can be used to identify whether a protein (or nucleic acid as discussed below) has sequence identity or similarity to a known sequence. Sequence identity and/or similarity is determined using standard techniques known in the art, 5 including, but not limited to, the local sequence identity algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the sequence identity alignment algorithm of Needleman & Wunsch, J. Mol. Biool. 48:443 (1970), by the search for similarity method of Pearson & Lipman, PNAS USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science 10 Drive, Madison, WI), the Best Fit sequence program described by Devereux et al., Nuc. Acid Res. 12:387-395 (1984), preferably using the default settings, or by inspection. Preferably, percent identity is calculated by FastDB based upon the following parameters: mismatch penalty of 1; gap penalty of 1; gap size penalty of 0.33; and joining penalty of 30, "Current Methods in Sequence Comparison and Analysis," Macromolecule Sequencing and Synthesis, Selected Methods and 15 Applications, pp 127-149 (1988), Alan R. Liss, Inc. An example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, J. Mol. Evol. 35:351-360 (1987); the method 20 is similar to that described by Higgins & Sharp CABIOS 5:151-153 (1989). Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps. Another example of a useful algorithm is the BLAST algorithm, described in Altschul et al., J. Mol. Biol. 215, 403-410, (1990) and Karlin et al., PNAS USA 90:5873-5787 (1993). A particularly useful 25 BLAST program is the WU-BLAST-2 program which was obtained from Altschul et al., Methods in Enzymoloqy, 266: 460-480 (1996); http://blast.wustl/edu/blast/ README.html]. WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span =1, overlap fraction = 0.125, word threshold (T) = 11. The HSP S and HSP S2 parameters are dynamic values and are established by the program 30 itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity. An additional useful algorithm is gapped BLAST as reported by Altschul et al. Nucleic Acids Res. 25:3389-3402. Gapped BLAST uses BLOSUM-62 substitution scores; threshold T parameter set 35 to 9; the two-hit method to trigger ungapped extensions; charges gap lengths of k a cost of 1 0+k; Xu set to 16, and Xg set to 40 for database search stage and to 67 for the output stage of the 7 WO 01/29072 PCT/USOO/41296 algorithms. Gapped alignments are triggered by a score corresponding to -22 bits. A % amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "longer" sequence in the aligned region. 5 The "longer" sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored). In a similar manner, "percent (%) nucleic acid sequence identity" with respect to the coding sequence of the polypeptides identified herein is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues in the coding sequence of 10 the p1 5 PAF cell cycle protein. A preferred method utilizes the BLASTN module of WU-BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively. The alignment may include the introduction of gaps in the sequences to be aligned. In addition, for sequences which contain either more or fewer amino acids than the protein encoded by the sequences in the Figures, it is understood that in one embodiment, the percentage of sequence 15 identity will be determined based on the number of identical amino acids in relation to the total number of amino acids. Thus, for example, sequence identity of sequences shorter than that shown in the Figure, as discussed below, will be determined using the number of amino acids in the shorter sequence, in one embodiment. In percent identity calculations relative weight is not assigned to various manifestations of sequence variation, such as, insertions, deletions, 20 substitutions, etc. In one embodiment, only identities are scored positively (+1) and all forms of sequence variation including gaps are assigned a value of "0", which obviates the need for a weighted scale or parameters as described below for sequence similarity calculations. Percent sequence identity can be calculated, for example, by dividing the number of matching identical residues by the total 25 number of residues of the "shorter" sequence in the aligned region and multiplying by 100. The "longer" sequence is the one having the most actual residues in the aligned region. As will be appreciated by those skilled in the art, the sequences of the present invention may contain sequencing errors. That is, there may be incorrect nucleosides, frameshifts, unknown nucleosides, or other types of sequencing errors in any of the sequences; however, the correct 30 sequences will fall within the homology and stringency definitions herein. P1 5 PAF cell cycle proteins of the present invention may be shorter or longer than the amino acid sequence encoded by the nucleic acid shown in the Figure. Thus, in a preferred embodiment, included within the definition of p1 5 PAF cell cycle proteins are portions or fragments of the amino acid sequence encoded by the nucleic acid sequence provided herein. In one embodiment herein, 35 fragments of p1 5 PAF cell cycle proteins are considered p1 5 PAF cell cycle proteins if a) they share at 8 WO 01/29072 PCT/USOO/41296 least one antigenic epitope; b) have at least the indicated sequence identity; c) and preferably have cell cycle biological activity as further defined herein. In some cases, where the sequence is used diagnostically, that is, when the presence or absence of p1 5 PAF cell cycle protein nucleic acid is determined, only the indicated sequence identity is required. The nucleic acids of the present 5 invention may also be shorter or longer than the sequences in the Figures. The nucleic acid fragments include any portion of the nucleic acids provided herein which have a sequence not exactly previously identified; fragments having sequences with the indicated sequence identity to that portion not previously identified are provided in an embodiment herein. In addition, as is more fully outlined below, p 15 PAF cell cycle proteins can be made that are longer 10 than those depicted in the Figures; for example, by the addition of epitope or purification tags, the addition of other fusion sequences, or the elucidation of additional coding and non-coding sequences. As described below, the fusion of a cell cycle peptide to a fluorescent peptide, such as Green Fluorescent Peptide (GFP) or its derivatives, including both Aquorea and Renilla species, is particularly preferred. 15 p 1 5 PAF cell cycle proteins may also be identified as encoded by cell cycle nucleic acids which hybridize to the sequence depicted in the Figure, or the complement thereof, as outlined herein. Hybridization conditions are further described below. In a preferred embodiment, when a p15PAF cell cycle protein is to be used to generate antibodies, a p1 5 PAF cell cycle protein must share at least one epitope or determinant with the full length protein. 20 By "epitope" or "determinant" herein is meant a portion of a protein which will generate and/or bind an antibody. Thus, in most instances, antibodies made to a smaller p15PAF cell cycle protein will be able to bind to the full length protein. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity. The term "antibody" includes antibody fragments, as are known in the art, including Fab Fab 2 , single chain antibodies 25 (Fv for example), chimeric antibodies, etc., either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies. In a preferred embodiment, the antibodies to a p 15 PAF cell cycle protein are capable of reducing or eliminating the biological function of the p 15 PAF cell cycle proteins described herein, as is described below. That is, the addition of anti-p1 5 PAF cell cycle protein antibodies (either polyclonal or 30 preferably monoclonal) to p1 5 PAF cell cycle proteins (or cells containing p1 5 PAF cell cycle proteins) may reduce or eliminate the cell cycle activity. Generally, at least a 25% decrease in activity is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred. The cell cycle antibodies of the invention specifically bind to p 15 PAF cell cycle proteins. By 35 "specifically bind" herein is meant that the antibodies bind to the protein with a binding constant in 9 WO 01/29072 PCT/USOO/41296 the range of at least 10- 10-6 M', with a preferred range being 10~7 - 10-9 M-1. Antibodies are further described below. In the case of the nucleic acid, the overall sequence identity of the nucleic acid sequence is commensurate with amino acid sequence identity but takes into account the degeneracy in the 5 genetic code and codon bias of different organisms. Accordingly, the nucleic acid sequence identity may be either lower or higher than that of the protein sequence. Thus the sequence identity of the nucleic acid sequence as compared to the nucleic acid sequence of the Figure is preferably greater than 75%, more preferably greater than about 80%, particularly greater than about 85% and most preferably greater than 90%. In some embodiments the sequence identity will 10 be as high as about 93 to 95 or 98%. In a preferred embodiment, a p1 5 PAF cell cycle nucleic acid encodes a p 1 5 PAF cell cycle protein. As will be appreciated by those in the art, due to the degeneracy of the genetic code, an extremely large number of nucleic acids may be made, all of which encode the p1 5 PAF cell cycle proteins of the present invention. Thus, having identified a particular amino acid sequence, those skilled in the 15 art could make any number of different nucleic acids, by simply modifying the sequence of one or more codons in a way which does not change the amino acid sequence of the p1 5 PAF cell cycle protein. In one embodiment, the nucleic acid is determined through hybridization studies. Thus, for example, nucleic acids which hybridize under high stringency to the nucleic acid sequence shown 20 in the Figure, or its complement is considered a cell cycle nucleic acid. High stringency conditions are known in the art; see for example Maniatis et al., Molecular Cloning: A Laboratory Manual, 2d Edition, 1989, and Short Protocols in Molecular Biology, ed. Ausubel, et al., both of which are hereby incorporated by reference. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher 25 temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10'C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined 30 ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30'C for 35 short probes (e.g. 10 to 50 nucleotides) and at least about 60'C for long probes (e.g. greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. 10 WO 01/29072 PCT/USOO/41296 In another embodiment, less stringent hybridization conditions are used; for example, moderate or low stringency conditions may be used, as are known in the art; see Maniatis and Ausubel, supra, .and Tijssen, supra. The p1 5 PAF cell cycle proteins and nucleic acids of the present invention are preferably 5 recombinant. As used herein and further defined below, "nucleic acid" may refer to either DNA or RNA, or molecules which contain both deoxy- and ribonucleotides. The nucleic acids include genomic DNA, cDNA and oligonucleotides including sense and anti-sense nucleic acids. Such nucleic acids may also contain modifications in the ribose-phosphate backbone to increase stability and half life of such molecules in physiological environments. 10 The nucleic acid may be double stranded, single stranded, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand ("Watson") also defines the sequence of the other strand ("Crick"); thus the sequences depicted in the Figures also include the complement of the sequence. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed in vitro, in general, by the 15 manipulation of nucleic acid by endonucleases, in a form not normally found in nature. Thus an isolated cell cycle nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e. using the in vivo cellular machinery 20 of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e. through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is 25 distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. For example, an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, preferably constituting at least about 0.5%, more preferably 30 at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. The definition includes the production of a p1 5 PAF cell cycle protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, 35 through the use of a inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as 11 WO 01/29072 PCT/USOO/41296 discussed below. In one embodiment, the present invention provides p1 5 PAF cell cycle protein variants. These variants fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA 5 encoding a p15PAF cell cycle protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant pl 5 PAF cell cycle protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the 10 variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the p1 5 PAF cell cycle protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below. While the site or region for introducing an amino acid sequence variation is predetermined, the 15 mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed cell cycle variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, M13 primer mutagenesis and PCR mutagenesis. 20 Screening of the mutants is done using assays of p1 5 PAF cell cycle protein activities. Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger. 25 Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the p1 5 PAF cell cycle protein are desired, substitutions are generally made in accordance with the following chart: 30 Chart I Original Residue Exemplary Substitutions Ala Ser Arg Lys Asn Gln, His 35 Asp Glu 12 WO 01/29072 PCT/USOO/41296 Cys Ser Gin Asn Glu Asp Gly Pro 5 His Asn, Gin lie Leu, Val Leu lie, Val Lys Arg, Gin, Glu Met Leu, Ile 10 Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp, Phe 15 Val Ile, Leu Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those shown in Chart 1. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at 5 the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or 10 by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine. The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analogue, although variants also are selected to modify the characteristics of the pl 5 PAF cell cycle proteins as needed. Alternatively, the variant may be 15 designed such that the biological activity of the p1 5 PAF cell cycle protein is altered. For example, glycosylation sites may be altered or removed. Covalent modifications of cell cycle polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a cell cycle polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains 20 or the N-or C-terminal residues of a cell cycle polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking cell cycle to a water-insoluble support matrix or surface for use in the method for purifying anti-cell cycle antibodies or screening assays, as is more fully 13 WO 01/29072 PCT/USOO/41296 described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2 phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azido salicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis (succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents 5 such as methyl-3-[(p-azidophenyl)dithio]propioimidate. Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the "-amino groups 10 of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group. Another type of covalent modification of the cell cycle polypeptide included within the scope of this 15 invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence cell cycle polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence cell cycle polypeptide. 20 Addition of glycosylation sites to cell cycle polypeptides may be accomplished by altering the amino acid sequence thereof. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence cell cycle polypeptide (for 0 linked glycosylation sites). The cell cycle amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the cell cycle polypeptide at 25 preselected bases such that codons are generated that will translate into the desired amino acids. Another means of increasing the number of carbohydrate moieties on the cell cycle polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981). 30 Removal of carbohydrate moieties present on the cell cycle polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties 35 on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987). Another type of covalent modification of cell cycle comprises linking the cell cycle polypeptide to 14 WO 01/29072 PCT/USOO/41296 one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. Cell cycle polypeptides of the present invention may also be modified in a way to form chimeric 5 molecules comprising a cell cycle polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a cell cycle polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the cell cycle polypeptide. The presence of such epitope-tagged forms of a cell cycle polypeptide can be 10 detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the cell cycle polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a cell cycle polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion 15 could be to the Fc region of an IgG molecule as discussed further below. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and 20 Cellular Bioloqy, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Enqineerinq, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnoloqy, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., 25 Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)]. In an embodiment herein, p1 5 PAF cell cycle proteins of the cell cycle family and p1 5 PAF cell cycle proteins from other organisms are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related p1 5 PAF cell cycle proteins from humans or other organisms. As will be appreciated by those in the 30 art, particularly useful probe and/or PCR primer sequences include the unique areas of the cell cycle nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art. It is therefore also understood that provided along with the sequences in the sequences listed herein 35 are portions of those sequences, wherein unique portions of 15 nucleotides or more are particularly preferred. The skilled artisan can routinely synthesize or cut a nucleotide sequence to the desired length. 15 WO 01/29072 PCT/USOO/41296 Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant cell cycle nucleic acid can be further used as a probe to identify and isolate other cell cycle nucleic acids. It can also be used as a "precursor" nucleic acid to make modified or variant cell cycle nucleic acids and proteins. 5 Using the nucleic acids of the present invention which encode a p1 5 PAF cell cycle protein, a variety of expression vectors are made. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the p1 5 PAF cell cycle protein. The term "control sequences" refers to 10 DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. 15 Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if 20 it is positioned so as to facilitate translation. As another example, operably linked refers to DNA sequences linked so as to be contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. The transcriptional and 25 translational regulatory nucleic acid will generally be appropriate to the host cell used to express the p 1 5 PAF cell cycle protein; for example, transcriptional and translational regulatory nucleic acid sequences from Bacillus are preferably used to express the p15PAF cell cycle protein in Bacillus. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells. 30 In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences. 35 Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present 16 WO 01/29072 PCT/USOO/41296 invention. In addition, the expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a procaryotic host for cloning and 5 amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art. 10 In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used. A preferred expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by 15 reference. P1 5 PAF cell cycle proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a p1 5 PAF cell cycle protein, under the appropriate conditions to induce or cause expression of the p1 5 PAF cell cycle protein. The conditions appropriate for p1 5 PAF cell cycle protein expression will vary with the choice of the 20 expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in 25 insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield. Appropriate host cells include yeast, bacteria, archebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Drosophila melangaster cells, Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, SF9 cells, C129 cells, 293 30 cells, Neurospora, BHK, CHO, COS, and HeLa cells, fibroblasts, Schwanoma cell lines, immortalized mammalian myeloid and lymphoid cell lines. In a preferred embodiment, the pl 5 PAF cell cycle proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral systems. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and 17 WO 01/29072 PCT/USOO/41296 initiating the downstream (3') transcription of a coding sequence for p15PAF cell cycle protein into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, using a located 25-30 base pairs upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase il to begin RNA 5 synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element (enhancer element), typically located within 100 to 200 base pairs upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host 10 range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter. Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site 15 specific post-translational cleavage and polyadenylation. Examples of transcription terminator and polyadenlytion signals include those derived form SV40. The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, 20 electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei. In a preferred embodiment, p15PAF cell cycle proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. A suitable bacterial promoter is any nucleic acid sequence capable of binding bacterial RNA 25 polymerase and initiating the downstream (3') transcription of the coding sequence of p1 5 PAF cell cycle protein into mRNA. A bacterial promoter has a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site. Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include 30 promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose and maltose, and sequences derived from biosynthetic enzymes such as tryptophan. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters 35 of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. 18 WO 01/29072 PCT/USOO/41296 In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. In E. coli, the ribosome binding site is called the Shine-Delgarno (SD) sequence and includes an initiation codon and a sequence 3-9 nucleotides in length located 3 - 11 nucleotides upstream of 5 the initiation codon. The expression vector may also include a signal peptide sequence that provides for secretion of the p 15 PAF cell cycle protein in bacteria. The signal sequence typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell, as is well known in the art. The protein is either secreted into the growth media (gram-positive bacteria) 10 or into the periplasmic space, located between the inner and outer membrane of the cell (gram negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, 15 kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others. 20 The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others. In one embodiment, p1 5 PAF cell cycle proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art. 25 In a preferred embodiment, p1 5 PAF cell cycle protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica. Preferred promoter sequences for expression in yeast include the inducible GAL1,10 promoter, the 30 promoters from alcohol dehydrogenase, enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase, hexokinase, phosphofructokinase, 3 phosphoglycerate mutase, pyruvate kinase, and the acid phosphatase gene. Yeast selectable markers include ADE2, HIS4, LEU2, TRP1, and ALG7, which confers resistance to tunicamycin; the neomycin phosphotransferase gene, which confers resistance to G418; and the CUP1 gene, 19 WO 01/29072 PCT/USOO/41296 which allows yeast to grow in the presence of copper ions. The p1 5 PAF cell cycle protein may also be made as a fusion protein, using techniques well known in the art. Thus, for example, for the creation of monoclonal antibodies, if the desired epitope is small, the p 15 PAF cell cycle protein may be fused to a carrier protein to form an immunogen. 5 Alternatively, the p15PAF cell cycle protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the p1 5 PAF cell cycle protein is a cell cycle peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes. Similarly, p 15 PAF cell cycle proteins of the invention can be linked to protein labels, such as green fluorescent protein (GFP), red fluorescent protein (RFP), blue fluorescent protein (BFP), yellow 10 fluorescent protein (YFP), etc. In one embodiment, the cell cycle nucleic acids, proteins and antibodies of the invention are labeled. By "labeled" herein is meant that a compound has at least one element, isotope or chemical compound attached to enable the detection of the compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, 15 which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the compound at any position. In a preferred embodiment, the p 15 PAF cell cycle protein is purified or isolated after expression.

P

15 PAF cell cycle proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification 20 methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the p1 5 PAF cell cycle protein may be purified using a standard anti-cell cycle antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see 25 Scopes, R., Protein Purification, Springer-Verlag, NY (1982). The degree of purification necessary will vary depending on the use of the p1 5 PAF cell cycle protein. In some instances no purification will be necessary. Once expressed and purified if necessary, the p1 5 PAF cell cycle proteins and nucleic acids are useful in a number of applications. 30 The nucleotide sequences (or their complement) encoding p1 5 PAF cell cycle proteins have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. P1 5 PAF cell cycle protein nucleic acid will also be useful for the preparation of p15PAF cell cycle proteins by the recombinant techniques described herein. 20 WO 01/29072 PCT/USOO/41296 The full-length native sequence p1 5 PAF cell cycle protein gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate other genes (for instance, those encoding naturally-occurring variants of p1 5 PAF cell cycle protein or p1 5 PAF cell cycle protein from other species) which have a desired sequence identity to the p 1 5 PAF cell cycle protein coding sequence. 5 Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from the nucleotide sequences herein or from genomic sequences including promoters, enhancer elements and introns of native sequences as provided herein. By way of example, a screening method will comprise isolating the coding region of the p1 5 PAF cell cycle protein gene using the known DNA sequence to synthesize a selected probe of about 40 bases. 10 Hybridization probes may be labeled by a variety of labels, including radionucleotides such as 2p or SS, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the p1 5 PAF cell cycle protein gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes. 15 Nucleotide sequences encoding a p15PAF cell cycle protein can also be used to construct hybridization probes for mapping the gene which encodes that p1 5 PAF cell cycle protein and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as in situ hybridization, linkage analysis against known chromosomal markers, and 20 hybridization screening with libraries. Nucleic acids which encode p1 5 PAF cell cycle protein or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the 25 animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding a p1 5 PAF cell cycle protein can be used to clone genomic DNA encoding a p1 5 PAF cell cycle protein in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express the desired DNA. 30 Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for the p1 5 PAF cell cycle protein transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding a p1 5 PAF cell cycle protein introduced into the germ line of the animal at an 35 embryonic stage can be used to examine the effect of increased expression of the desired nucleic acid. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the 21 WO 01/29072 PCT/USOO/41296 pathological condition, compared to. untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition. Alternatively, non-human homologues of the p15PAF cell cycle protein can be used to construct a 5 p 15 PAF cell cycle protein "knock out" animal which has a defective or altered gene encoding a p1 5 PAF cell cycle protein as a result of homologous recombination between the endogenous gene encoding a p15PAF cell cycle protein and altered genomic DNA encoding a p 15 PAF cell cycle protein introduced into an embryonic cell of the animal. For example, cDNA encoding a p1 5 PAF cell cycle protein can be used to clone genomic DNA encoding a p1 5 PAF cell cycle protein in accordance with 10 established techniques. A portion of the genomic DNA encoding a p1 5 PAF cell cycle protein can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, Ce, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic 15 stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., Cell, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can 20 then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development 25 of pathological conditions due to absence of the p1 5 PAF cell cycle protein. It is understood that the models described herein can be varied. For example, "knock-in" models can be formed, or the models can be cell-based rather than animal models. Nucleic acid encoding the cell cycle polypeptides, antagonists or agonists may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve in 30 vivo synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes in 35 vivo. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik et al., Proc. Natl. Acad. Sci. USA 83, 4143-4146 [1986]). The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively 22 WO 01/29072 PCT/USOO/41296 charged phosphodiester groups by uncharged groups. There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells in vitro, or in vivo in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into 5 mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred in vivo gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau et al., Trends in Biotechnoloqy 11, 205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the 10 target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular 15 localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Nati. Acad. Sci. USA 87 3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson et aL., Science 256, 808-813 (1992). In a preferred embodiment, the p 1 5 PAF cell cycle proteins, nucleic acids, variants, modified 20 proteins, cells and/or transgenics containing the said nucleic acids or proteins are used in screening assays. Identification of the p 15 PAF cell cycle protein provided herein permits the design of drug screening assays for compounds that bind or interfere with the binding to the p1 5 PAF cell cycle protein and for compounds which modulate cell cycle activity. The assays described herein preferably utilize the human p15PAF cell cycle protein, although other 25 mammalian proteins may also be used, including rodents (mice, rats, hamsters, guinea pigs, etc.), farm animals (cows, sheep, pigs, horses, etc.) and primates. These latter embodiments may be preferred in the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative p1 5 PAF cell cycle proteins may be used, including deletion p1 5 PAF cell cycle proteins as outlined above. 30 In a preferred embodiment, the methods comprise combining a cell cyle protein and a candidate bioactive agent, and determining the binding of the candidate agent to the p1 5 PAF cell cycle protein. In other embodiments, further discussed below, binding interference or bioactivity is determined. The term "candidate bioactive agent" or "exogeneous compound" as used herein describes any molecule, e.g., protein, small organic molecule, carbohydrates (including polysaccharides), 35 polynucleotide, lipids, etc. Generally a plurality of assay mixtures are run in parallel with different 23 WO 01/29072 PCT/USOO/41296 agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection. In addition, positive controls, i.e. the use of agents known to alter cell cycling, may be used. For example, p21 is a molecule known to arrest cells in the G1 cell phase, by binding G1 5 cyclin-CDK complexes. In addition, as shown in the examples, p21 competes with p 1 5 PAF for binding to PCNA and assays may be designed accordingly. Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for 10 structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, 15 steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides. Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of 20 randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, 25 amidification to produce structural analogs. In a preferred embodiment, a library of different candidate bioactive agents are used. Preferably, the library should provide a sufficiently structurally diverse population of randomized agents to effect a probabilistically sufficient range of diversity to allow binding to a particular target. Accordingly, an interaction library should be large enough so that at least one of its members will 30 have a structure that gives it affinity for the target. Although it is difficult to gauge the required absolute size of an interaction library, nature provides a hint with the immune response: a diversity of 107-10" different antibodies provides at least one combination with sufficient affinity to interact with most potential antigens faced by an organism. Published in vitro selection techniques have also shown that a library size of 10 7 to 108 is sufficient to find structures with affinity for the target. 35 A library of all combinations of a peptide 7 to 20 amino acids in length, such as generally proposed herein, has the potential to code for 207 (109) to 2020 . Thus, with libraries of 107 to 108 different molecules the present methods allow a "working" subset of a theoretically complete interaction 24 WO 01/29072 PCT/USOO/41296 library for 7 amino acids, and a subset of shapes for the 2020 library. Thus, in a preferred embodiment, at least 106, preferably at least 107, more preferably at least 108 and most preferably at least 10 9 different sequences are simultaneously analyzed in the subject methods. Preferred methods maximize library size and diversity. 5 In a preferred embodiment, the candidate bioactive agents are proteins. By "protein" herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides. The protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures. Thus "amino acid", or "peptide residue", as used herein means both naturally occurring and synthetic amino acids. For example, homo 10 phenylalanine, citrulline and noreleucine are considered amino acids for the purposes of the invention. "Amino acid" also includes imino acid residues such as proline and hydroxyproline. The side chains may be in either the (R) or the (S) configuration. In the preferred embodiment, the amino acids are in the (S) or L-configuration. If non-naturally occurring side chains are used, non amino acid substituents may be used, for example to prevent or retard in vivo degradations. 15 Chemical blocking groups or other chemical substituents may also be added. In a preferred embodiment, the candidate bioactive agents are naturally occurring proteins or fragments of naturally occurring proteins. Thus, for example, cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of procaryotic and eukaryotic proteins may be made for screening in the systems described herein. 20 Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. In a preferred embodiment, the candidate bioactive agents are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is 25 outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or 30 nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents. In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For 35 example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, for example, of hydrophobic amino acids, hydrophilic residues, sterically biased 25 WO 01/29072 PCT/USOO/41296 (either small or large) residues, towards the creation of cysteines, for cross-linking, prolines for SH 3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc. In a preferred embodiment, the candidate bioactive agents are nucleic acids. By "nucleic acid" or 5 "oligonucleotide" or grammatical equivalents herein means at least two nucleotides covalently linked together. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, as outlined below, nucleic acid analogs are included that may have alternate backbones, comprising, for example, phosphoramide (Beaucage, et al., Tetrahedron, 49(10):1925 (1993) and references therein; Letsinger, J. Orq. Chem., 35:3800 10 (1970); Sprinzl, et al., Eur. J. Biochem., 81:579 (1977); Letsinger, et al., Nucl. Acids Res., 14:3487 (1986); Sawai, et al., Chem. Lett., 805 (1984), Letsinger, et al., J. Am. Chem. Soc., 110:4470 (1988); and Pauwels, et al., Chemica Scripta, 26:141 (1986)), phosphorothioate (Mag, et al., Nucleic Acids Res., 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu, et al., J. Am. Chem. Soc., 111:2321 (1989)), 0-methylphophoroamidite linkages (see Eckstein, 15 Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc., 114:1895 (1992); Meier, et al., Chem. Int. Ed. Engl., 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson, et al., Nature, 380:207 (1996), all of which are incorporated by reference)). Other analog nucleic acids include those with positive backbones (Denpcy, et al., Proc. Natl. Acad. Sci. USA, 92:6097 (1995)); non 20 ionic backbones (U.S. Patent Nos. 5,386,023; 5,637,684; 5,602,240; 5,216,141; and 4,469,863; Kiedrowshi, et al., Anciew. Chem. Intl. Ed. English, 30:423 (1991); Letsinger, et al., J. Am. Chem. Soc., 110:4470 (1988); Letsinger, et al., Nucleoside & Nucleotide, 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker, et al., Bioorqanic & Medicinal Chem. Lett., 4:395 (1994); 25 Jeffs, et al., J. Biomolecular NMR, 34:17 (1994); Tetrahedron Lett., 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within the definition of nucleic acids (see Jenkins, et al., Chem. Soc. Rev., (1995) pp. 169 30 176). Several nucleic acid analogs are described in Rawls, C & E News, June 2, 1997, page 35. All of these references are hereby expressly incorporated by reference. These modifications of the ribose-phosphate backbone may be done to facilitate the addition of additional moieties such as labels, or to increase the stability and half-life of such molecules in physiological environments. In addition, mixtures of naturally occurring nucleic acids and analogs can be made. Alternatively, 35 mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid contains any combination of deoxyribo- and ribo-nucleotides, and any combination of bases, including uracil, adenine, 26 WO 01/29072 PCT/USOO/41296 thymine, cytosine, guanine, inosine, xathanine hypoxathanine, isocytosine, iiogU Ariine, A As described above generally for proteins, nucleic acid candidate bioactive agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eukaryotic genomes may be used as is outlined above for 5 proteins. In a preferred embodiment, the candidate bioactive agents are organic chemical moieties, a wide variety of which are available in the literature. In a preferred embodiment, the candidate bioactive agents are linked to a fusion partner. By "fusion partner' or "functional group" herein is meant a sequence that is associated with the 10 candidate bioactive agent, that confers upon all members of the library in that class a common function or ability. Fusion partners can be heterologous (i.e. not native to the host cell), or synthetic (not native to any cell). Suitable fusion partners include, but are not limited to: a) presentation structures, which provide the candidate bioactive agents in a conformationally restricted or stable form; b) targeting sequences, which allow the localization of the candidate 15 bioactive agent into a subcellular or extracellular compartment; c) rescue sequences which allow the purification or isolation of either the candidate bioactive agents or the nucleic acids encoding them; d) stability sequences, which confer stability or protection from degradation to the candidate bioactive agent or the nucleic acid encoding it, for example resistance to proteolytic degradation; e) dimerization sequences, to allow for peptide dimerization; or f) any combination of a), b), c), d), and 20 e), as well as linker sequences as needed. In one embodiment of the methods described herein, portions of p1 5 PAF cell cycle proteins are utilized; in a preferred embodiment, portions having cell cycle activity are used. Cell cycle activity is described further below and includes binding activity to PCNA or p1 5 PAF cell cycle protein modulators as further described below. In addition, the assays described herein may utilize either 25 isolated p15PAF cell cycle proteins or cells comprising the p 15 PAF cell cycle proteins. Generally, in a preferred embodiment of the methods herein, for example for binding assays, the p 15 PAF cell cycle protein or the candidate agent is non-diffusibly bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily 30 separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon TM, etc. Microtiter plates and arrays are especially convenient because a large number of 35 assays can be carried out simultaneously, using small amounts of reagents and samples. In some 27 WO 01/29072 PCT/USOO/41296 cases magnetic beads and the like are included. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or 5 activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. In some embodiments, PCNA can be used. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety. 10 Also included in this invention are screening assays wherein solid supports are not used; examples of such are described below. In a preferred embodiment, the p15PAF cell cycle protein is bound to the support, and a candidate bioactive agent is added to the assay. Alternatively, the candidate agent is bound to the support and the p15PAF cell cycle protein is added. Novel binding agents include specific antibodies, 15 non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like. 20 The determination of the binding of the candidate bioactive agent to the p1 5 PAF cell cycle protein may be done in a number of ways. In a preferred embodiment, the candidate bioactive agent is labelled, and binding determined directly. For example, this may be done by attaching all or a portion of the p1 5 PAF cell cycle protein to a solid support, adding a labelled candidate agent (for example a fluorescent label), washing off excess reagent, and determining whether the label is 25 present on the solid support. Various blocking and washing steps may be utilized as is known in the art. By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g. radioisotope, fluorescers, enzyme, antibodies, particles such as magnetic particles, chemiluminescers, or specific binding molecules, etc. Specific binding 30 molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal. In some embodiments, only one of the components is labeled. For example, the proteins (or 35 proteinaceous candidate agents) may be labeled at tyrosine positions using 1251, or with fluorophores. Alternatively, more than one component may be labeled with different labels; using 28 WO 01/29072 PCT/USOO/41296 1251 for the proteins, for example, and a fluorophor for the candidate agents. In a preferred embodiment, the binding of the candidate bioactive agent is determined through the use of competitive binding assays. In this embodiment, the competitor is a binding moiety known to bind to the target molecule (i.e. p1 5 PAF cell cycle protein), such as an antibody, peptide, binding 5 partner, ligand, etc. In a preferred embodiment, the competitor is PCNA. Under certain circumstances, there may be competitive binding as between the bioactive agent and the binding moiety, with the binding moiety displacing the bioactive agent. This assay can be used to determine candidate agents which interfere with binding between p1 5 PAF cell cycle proteins and PCNA, or which compete with p21 for binding to PCNA. "Interference of binding" as used herein 10 means that native binding of the pl 5 PAF cell cycle protein differs in the presence of the candidate agent. The binding can be eliminated or can be with a reduced affinity. Therefore, in one embodiment, interference is caused by, for example, a conformation change, rather than direct competition for the native binding site. In one embodiment, the candidate bioactive agent is labeled. Either the candidate bioactive agent, 15 or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at any temperature which facilitates optimal activity, typically between 4 and 40'C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high through put screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then 20 added, and the presence or absence of the labeled component is followed, to indicate binding. In a preferred embodiment, the competitor is added first, followed by the candidate bioactive agent. Displacement of the competitor is an indication that the candidate bioactive agent is binding to the p 15 PAF cell cycle protein and thus is capable of binding to, and potentially modulating, the activity of the p 15 PAF cell cycle protein. In this embodiment, either component can be labeled. Thus, for 25 example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate bioactive agent is labeled, the presence of the label on the support indicates displacement. In an alternative embodiment, the candidate bioactive agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that 30 the bioactive agent is bound to the p1 5 PAF cell cycle protein with a higher affinity. Thus, if the candidate bioactive agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the candidate agent is capable of binding to the p1 5 PAF cell cycle protein. In a preferred embodiment, the methods comprise differential screening to identity bioactive agents 35 that are capable of modulating the activity of the p1 5 PAF cell cycle proteins. Such assays can be 29 WO 01/29072 PCT/USOO/41296 done with the p1 5 PAF cell cycle protein or cells comprising said p1 5 PAF cell cycle protein. In one embodiment, the methods comprise combining an pl 5 PAF cell cycle protein and a competitor in a first sample. A second sample comprises a candidate bioactive agent, an p1 5 PAF cell cycle protein and a competitor. The binding of the competitor is determined for both samples, and a change, or 5 difference in binding between the two samples indicates the presence of an agent capable of binding to the p 1 5 PAF cell cycle protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the p15PAF cell cycle protein. Alternatively, a preferred embodiment utilizes differential screening to identify drug candidates that 10 bind to the native p1 5 PAF cell cycle protein, but cannot bind to modified pl 5 PAF cell cycle proteins. The structure of the p1 5 PAF cell cycle protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect cell cycle bioactivity are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein. 15 Positive controls and negative controls may be used in the assays. Preferably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be 20 counted in a scintillation counter to determine the amount of bound compound. A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, 25 anti-microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding. Screening for agents that modulate the activity of cell cycle may also be done. In a preferred embodiment, methods for screening for a bioactive agent capable of modulating the activity of cell cycle comprise the steps of adding a candidate bioactive agent to a sample of a p1 5 PAF cell cycle 30 protein (or cells comprising a p1 5 PAF cell cycle protein) and determining an alteration in the biological activity of the p1 5 PAF cell cycle protein. "Modulating the activity of a p1 5 PAF cell cycle protein" includes an increase in activity, a decrease in activity, or a change in the type or kind of activity present. Thus, in this embodiment, the candidate agent should both bind to cell cycle (although this may not be necessary), and alter its biological or biochemical activity as defined 35 herein. The methods include both in vitro screening methods, as are generally outlined above, and in vivo screening of cells for alterations in the presence, distribution, activity or amount of p 5 PAF 30 WO 01/29072 PCT/USOO/41296 cell cycle protein. Thus, in this embodiment, the methods comprise combining an cell cycle sample and a candidate bioactive agent, and evaluating the effect on the cell cycle. By "cell cycle activity", "p15PAF cell cycle protein activity" or grammatical equivalents herein is meant at least one of the p15PAF cell 5 cycle protein's biological activities, including, but not limited to, its ability to affect the cell cycle, bind to PCNA, bind to CDK 2 and 3, increase expression in tumor tissue, compete with p21 or FEN1 to bind PCNA, modulation of DNA replication, and modulation of DNA repair. In a preferred embodiment, the activity of the p1 5 PAF cell cycle protein is decreased; in another preferred embodiment, the activity of the p1 5 PAF cell cycle protein is increased. Thus, bioactive 10 agents that are antagonists are preferred in some embodiments, and bioactive agents that are agonists may be preferred in other embodiments. In a preferred embodiment, the invention provides methods for screening for bioactive agents capable of modulating the activity of an p15PAF cell cycle protein. The methods comprise adding a candidate bioactive agent, as defined above, to a cell comprising p1 5 PAF cell cycle proteins. 15 Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes an p1 5 PAF cell cycle protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells. Detection of cell cycle regulation may be done as will be appreciated by those in the art. In one embodiment, indicators of the cell cycle are used. There are a number of parameters that may be 20 evaluated or assayed to allow the detection of alterations in cell cycle regulation, including, but not limited to, cell viability assays, assays to determine whether cells are arrested at a particular cell cycle stage ("cell proliferation assays"), and assays to determine at which cell stage the cells have arrested ("cell phase assays"). By assaying or measuring one or more of these parameters, it is possible to detect not only alterations in cell cycle regulation, but alterations of different steps of 25 the cell cycle regulation pathway. This may be done to evaluate native cells, for example to quantify the aggressiveness of a tumor cell type, or to evaluate the effect of candidate drug agents that are being tested for their effect on cell cycle regulation. In this manner, rapid, accurate screening of candidate agents may be performed to identify agents that modulate cell cycle regulation. 30 Thus, the present compositions and methods are useful to elucidate bioactive agents that can cause a cell or a population of cells to either move out of one growth phase and into another, or arrest in a growth phase. In some embodiments, the cells are arrested in a particular growth phase, and it is desirable to either get them out of that phase or into a new phase. Alternatively, it may be desirable to force a cell to arrest in a phase, for example G1, rather than continue to move 35 through the cell cycle. Similarly, it may be desirable in some circumstances to accelerate a non 31 WO 01/29072 PCT/USOO/41296 arrested but slowly moving population of cells into either the next phase or just through the cell cycle, or to delay the onset of the next phase. For example, it may be possible to alter the activities of certain enzymes, for example kinases, phosphatases, proteases or ubiquitination enzymes, that contribute to initiating cell phase changes. 5 In a preferred embodiment, the methods outlined herein are done on cells that are not arrested in the G1 phase; that is, they are rapidly or uncontrollably growing and replicating, such as tumor cells. In this manner, candidate agents are evaluated to find agents that can alter the cell cycle regulation, i.e. cause the cells to arrest at cell cycle checkpoints, such as in G1 (although arresting in other phases such as S, G2 or M are also desirable). Alternatively, candidate agents are 10 evaluated to find agents that can cause proliferation of a population of cells, i.e. that allow cells that are generally arrested in G1 to start proliferating again; for example, peripheral blood cells, terminally differentiated cells, stem cells in culture, etc. Accordingly, the invention provides methods for screening for alterations in cell cycle regulation of a population of cells. By "alteration" or "modulation" (used herein interchangeably), is generally 15 meant one of two things. In a preferred embodiment, the alteration results in a change in the cell cycle of a cell, i.e. a proliferating cell arrests in any one of the phases, or an arrested cell moves out of its arrested phase and starts the cell cycle, as compared to another cell or in the same cell under different conditions. Alternatively, the progress of a cell through any particular phase may be altered; that is, there may be an acceleration or delay in the length of time it takes for the cells to 20 move thorough a particular growth phase. For example, the cell may be normally undergo a G1 phase of several hours; the addition of an agent may prolong the G1 phase. The measurements can be determined wherein all of the conditions are the same for each measurement, or under various conditions, with or without bioactive agents, or at different stages of the cell cycle process. For example, a measurement of cell cycle regulation can be determined 25 in a cell or cell population wherein a candidate bioactive agent is present and wherein the candidate bioactive agent is absent. In another example, the measurements of cell cycle regulation are determined wherein the condition or environment of the cell or populations of cells differ from one another. For example, the cells may be evaluated in the presence or absence or previous or subsequent exposure of physiological signals, for example hormones, antibodies, 30 peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the measurements of cell cycle regulation are determined at different stages of the cell cycle process. In yet another example, the measurements of cell cycle regulation are taken wherein the conditions are the same, and the alterations are between one cell or cell population 35 and another cell or cell population. By a "population of cells" or "library of cells" herein is meant at least two cells, with at least about 32 WO 01/29072 PCT/USOO/41296 103 being preferred, at least about 106 being particularly preferred, and at least about 108 to 10 9 being especially preferred. The population or sample can contain a mixture of different cell types from either primary or secondary cultures although samples containing only a single cell type are preferred, for example, the sample can be from a cell line, particularly tumor cell lines, as outlined 5 below. The cells may be in any cell phase, either synchronously or not, including M, G1, S, and G2. In a preferred embodiment, cells that are replicating or proliferating are used; this may allow the use of retroviral vectors for the introduction of candidate bioactive agents. Alternatively, non replicating cells may be used, and other vectors (such as adenovirus and lentivirus vectors) can be used. In addition, although not required, the cells are compatible with dyes and antibodies. 10 Preferred cell types for use in the invention include, but are not limited to, mammalian cells, including animal (rodents, including mice, rats, hamsters and gerbils), primates, and human cells, particularly including tumor cells of all types, including breast, skin, lung, cervix, colonrectal, leukemia, brain, etc. In a preferred embodiment, the methods comprise assaying one or more of several different cell 15 parameters, including, but not limited to, cell viability, cell proliferation, and cell phase. Other parameters include dna replication, dna repair, binding, interference of binding, inhibition of tumor growth. In a preferred embodiment, cell viability is assayed, to ensure that a lack of cellular change is due to experimental conditions (i.e. the introduction of a candidate bioactive agent) not cell death. 20 There are a variety of suitable cell viability assays which can be used, including, but not limited to, light scattering, viability dye staining, and exclusion dye staining. In a preferred embodiment, a light scattering assay is used as the viability assay, as is well known in the art. For example, when viewed in the FACS, cells have particular characteristics as measured by their forward and 90 degree (side) light scatter properties. These scatter properties 25 represent the size, shape and granule content of the cells. These properties account for two parameters to be measured as a readout for the viability. Briefly, the DNA of dying or dead cells generally condenses, which alters the 900 scatter; similarly, membrane blebbing can alter the forward scatter. Alterations in the intensity of light scattering, or the cell-refractive index indicate alterations in viability. 30 Thus, in general, for light scattering assays, a live cell population of a particular cell type is evaluated to determine it's forward and side scattering properties. This sets a standard for scattering that can subsequently be used. In a preferred embodiment, the viability assay utilizes a viability dye. There are a number of known viability dyes that stain dead or dying cells, but do not stain growing cells. For example, annexin V 33 WO 01/29072 PCT/USOO/41296 is a member of a protein family which displays specific binding to phospholipid (phosphotidylserine) in a divalent ion dependent manner. This protein has been widely used for the measurement of apoptosis (programmed cell death) as cell surface exposure of phosphatidylserine is a hallmark early signal of this process. Suitable viability dyes include, but are not limited to, annexin, ethidium 5 homodimer-1, DEAD Red, propidium iodide, SYTOX Green, etc., and others known in the art; see the Molecular Probes Handbook of Fluorescent Probes and Research Chemicals, Haugland, Sixth Edition, hereby incorporated by reference; see Apoptosis Assay on page 285 in particular, and Chapter 16. Protocols for viability dye staining for cell viability are known, see Molecular Probes catalog, supra. 10 In this embodiment, the viability dye such as annexin is labeled, either directly or indirectly, and combined with a cell population. Annexin is commercially available, i.e., from PharMingen, San Diego, California, or Caltag Laboratories, Millbrae, California. Preferably, the viability dye is provided in a solution wherein the dye is in a concentration of about 100 ng/ml to about 500 ng/ml, more preferably, about 500 ng/ml to about 1 pg/ml, and most preferably, from about 1 pg/ml to 15 about 5 pg/ml. In a preferred embodiment, the viability dye is directly labeled; for example, annexin may be labeled with a fluorochrome such as fluorecein isothiocyanate (FITC), Alexa dyes, TRITC, AMCA, APC, tri-color, Cy-5, and others known in the art or commercially available. In an alternate preferred embodiment, the viability dye is labeled with a first label, such as a hapten such as biotin, and a secondary fluorescent label is used, such as fluorescent streptavidin. Other first and second 20 labeling pairs can be used as will be appreciated by those in the art. Once added, the viability dye is allowed to incubate with the cells for a period of time, and washed, if necessary. The cells are then sorted as outlined below to remove the non-viable cells. In a preferred embodiment, exclusion dye staining is used as the viability assay. Exclusion dyes are those which are excluded from living cells, i.e. they are not taken up passively (they do not 25 permeate the cell membrane of a live cell). However, due to the permeability of dead or dying cells, they are taken up by dead cells. Generally, but not always, the exclusion dyes bind to DNA, for example via intercalation. Preferably, the exclusion dye does not fluoresce, or fluoresces poorly, in the absence of DNA; this eliminates the need for a wash step. Alternatively, exclusion dyes that require the use of a secondary label may also be used. Preferred exclusion dyes 30 include, but are not limited to, ethidium bromide; ethidium homodimer-1; propidium iodine; SYTOX green nucleic acid stain; Calcein AM, BCECF AM; fluorescein diacetate; TOTO@ and TO-PROTM (from Molecular Probes; supra, see chapter 16) and others known in the art. Protocols for exclusion dye staining for cell viability are known, see the Molecular Probes catalog, supra. In general, the exclusion dye is added to the cells at a concentration of from about 100 35 ng/ml to about 500 ng/ml, more preferably, about 500 ng/mI to about 1 pg/ml, and most preferably, from about 0.1 pg/ml to about 5 pg/ml, with about 0.5 pg/mI being particularly preferred. The cells 34 WO 01/29072 PCT/USOO/41296 and the exclusion dye are incubated for some period of time, washed, if necessary, and then the cells sorted as outlined below, to remove non-viable cells from the population. In addition, there are other cell viability assays which may be run, including for example enzymatic assays, which can measure extracellular enzymatic activity of either live cells (i.e. secreted 5 proteases, etc.), or dead cells (i.e. the presence of intracellular enzymes in the media; for example, intracellular proteases, mitochondrial enzymes, etc.). See the Molecular Probes Handbook of Fluorescent Probes and Research Chemicals, Haugland, Sixth Edition, hereby incorporated by reference; see chapter 16 in particular. In a preferred embodiment, at least one cell viability assay is run, with at least two different cell 10 viability assays being preferred, when the fluors are compatible. When only I viability assay is run, a preferred embodiment utilizes light scattering assays (both forward and side scattering). When two viability assays are run, preferred embodiments utilize light scattering and dye exclusion, with light scattering and viability dye staining also possible, and all three being done in some cases as well. Viability assays thus allow the separation of viable cells from non-viable or dying cells. 15 In addition to a cell viability assay, a preferred embodiment utilizes a cell proliferation assay. By "proliferation assay" herein is meant an assay that allows the determination that a cell population is either proliferating, i.e. replicating, or not replicating. In a preferred embodiment, the proliferation assay is a dye inclusion assay. A dye inclusion assay relies on dilution effects to distinguish between cell phases. Briefly, a dye (generally a fluorescent 20 dye as outlined below) is introduced to cells and taken up by the cells. Once taken up, the dye is trapped in the cell, and does not diffuse out. As the cell population divides, the dye is proportionally diluted. That is, after the introduction of the inclusion dye, the cells are allowed to incubate for some period of time; cells that lose fluorescence over time are dividing, and the cells that remain fluorescent are arrested in a non-growth phase. 25 Generally, the introduction of the inclusion dye may be done in one of two ways. Either the dye cannot passively enter the cells (e.g. it is charged), and the cells must be treated to take up the dye; for example through the use of a electric pulse. Alternatively, the dye can passively enter the cells, but once taken up, it is modified such that it cannot diffuse out of the cells. For example, enzymatic modification of the inclusion dye may render it charged, and thus unable to diffuse out of 30 the cells. For example, the Molecular Probes CellTrackerTM dyes are fluorescent chloromethyl derivatives that freely diffuse into cells, and then glutathione S-transferase-mediated reaction produces membrane impermeant dyes. Suitable inclusion dyes include, but are not limited to, the Molecular Probes line of CellTracker TM dyes , including, but not limited to CellTrackerTM Blue, CellTrackerTM Yellow-Green, CellTrackerTM 35 WO 01/29072 PCT/USOO/41296 Green, CellTracker TM Orange, PKH26 (Sigma), and others known in the art; see the Molecular Probes Handbook, supra; chapter 15 in particular. In general, inclusion dyes are provided to the cells at a concentration ranging from about 100 ng/ml to about 5 pg/ml, with from about 500 ng/ml to about 1 pg/ml being preferred. Awash 5 step may or may not be used. In a preferred embodiment, a candidate bioactive agent is combined with the cells as described herein. The cells and the inclusion dye are incubated for some period of time, to allow cell division and thus dye dilution. The length of time will depend on the cell cycle time for the particular cells; in general, at least about 2 cell divisions are preferred, with at least about 3 being particularly preferred and at least about 4 being especially preferred. The cells are 10 then sorted as outlined below, to create populations of cells that are replicating and those that are not. As will be appreciated by those in the art, in some cases, for example when screening for anti proliferation agents, the bright (i.e. fluorescent) cells are collected; in other embodiments, for example for screening for proliferation agents, the low fluorescence cells are collected. Alterations are determined by measuring the fluorescence at either different time points or in different cell 15 populations, and comparing the determinations to one another or to standards. In a preferred embodiment, the proliferation assay is an antimetabolite assay. In general, antimetabolite assays find the most use when agents that cause cellular arrest in G1 or G2 resting phase is desired. In an antimetabolite proliferation assay, the use of a toxic antimetabolite that will kill dividing cells will result in survival of only those cells that are not dividing. Suitable 20 antimetabolites include, but are not limited to, standard chemotherapeutic agents such as methotrexate, cisplatin, taxol, hydroxyurea, nucleotide analogs such as AraC, etc. In addition, antimetabolite assays may include the use of genes that cause cell death upon expression. The concentration at which the antimetabolite is added will depend on the toxicity of the particular antimetabolite, and will be determined as is known in the art. The antimetabolite is added and the 25 cells are generally incubated for some period of time; again, the exact period of time will depend on the characteristics and identity of the antimetabolite as well as the cell cycle time of the particular cell population. Generally, a time sufficient for at least one cell division to occur. In a preferred embodiment, at least one proliferation assay is run, with more than one being preferred. Thus, a proliferation assay results in a population of proliferating cells and a population 30 of arrested cells. Moreover, other proliferation assays may be used, i.e., colorimetric assays known in the art. In a preferred embodiment, either after or simultaneously with one or more of the proliferation assays outlined above, at least one cell phase assay is done. A "cell phase" assay determines at which cell phase the cells are arrested, M, G1, S, or G2. 36 WO 01/29072 PCT/USOO/41296 In a preferred embodiment, the cell phase assay is a DNA binding dye assay. Briefly, a DNA binding dye is introduced to the cells, and taken up passively. Once inside the cell, the DNA binding dye binds to DNA, generally by intercalation, although in some cases, the dyes can be either major or minor groove binding compounds. The amount of dye is thus directly correlated to 5 the amount of DNA in the cell, which varies by cell phase; G2 and M phase cells have twice the DNA content of G1 phase cells, and S phase cells have an intermediate amount, depending on at what point in S phase the cells are. Suitable DNA binding dyes are permeant, and include, but are not limited to, Hoechst 33342 and 33258, acridine orange, 7-AAD, LDS 751, DAPI, and SYTO 16, Molecular Probes Handbook, supra; chapters 8 and 16 in particular. 10 In general, the DNA binding dyes are added in concentrations ranging from about 1 pg/ml to about 5 pg/ml. The dyes are added to the cells and allowed to incubate for some period of time; the length of time will depend in part on the dye chosen. In one embodiment, measurements are taken immediately after addition of the dye. The cells are then sorted as outlined below, to create populations of cells that contain different amounts of dye, and thus different amounts of DNA; in 15 this way, cells that are replicating are separated from those that are not. As will be appreciated by those in the art, in some cases, for example when screening for anti-proliferation agents, cells with the least fluorescence (and thus a single copy of the genome) can be separated from those that are replicating and thus contain more than a single genome of DNA. Alterations are determined by measuring the fluorescence at either different time points or in different cell populations, and 20 comparing the determinations to one another or to standards. In a preferred embodiment, the cell phase assay is a cyclin destruction assay. In this embodiment, prior to screening (and generally prior to the introduction of a candidate bioactive agent, as outlined below), a fusion nucleic acid is introduced to the cells. The fusion nucleic acid comprises nucleic acid encoding a cyclin destruction box and a nucleic acid encoding a detectable molecule. "Cyclin 25 destruction boxes" are known in the art and are sequences that cause destruction via the ubiquitination pathway of proteins containing the boxes during particular cell phases. That is, for example, G1 cyclins may be stable during G1 phase but degraded during S phase due to the presence of a G1 cyclin destruction box. Thus, by linking a cyclin destruction box to a detectable molecule, for example green fluorescent protein, the presence or absence of the detectable 30 molecule can serve to identify the cell phase of the cell population. In a preferred embodiment, multiple boxes are used, preferably each with a different fluor, such that detection of the cell phase can occur. A number of cyclin destruction boxes are known in the art, for example, cyclin A has a destruction box comprising the sequence RTVLGVIGD; the destruction box of cyclin B1 comprises the 35 sequence RTALGDIGN. See Glotzer et al., Nature 349:132-138 (1991). Other destruction boxes are known as well: YMTVSIIDRFMQDSCVPKKMLQLVGVT (rat cyclin B); KFRLLQETMYMTVSIIDRFMQNSCVPKK (mouse cyclin B); 37 WO 01/29072 PCT/USOO/41296 RAILIDWLIQVQMKFRLLQETMYMTVS (mouse cyclin B1); DRFLQAQLVCRKKLQVVGITALLLASK (mouse cyclin B2); and MSVLRGKLQLVGTAAMLL (mouse cyclin A2). The nucleic acid encoding the cyclin destruction box is operably linked to nucleic acid encoding a detectable molecule. The fusion proteins are constructed by methods known in the art. For 5 example, the nucleic acids encoding the destruction box is ligated to a nucleic acid encoding a detectable molecule. By "detectable molecule" herein is meant a molecule that allows a cell or compound comprising the detectable molecule to be distinguished from one that does not contain it, i.e., an epitope, sometimes called an antigen TAG, a specific enzyme, or a fluorescent molecule. Preferred fluorescent molecules include but are not limited to green fluorescent protein (GFP), blue 10 fluorescent protein (BFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), and enzymes including luciferase and -galactosidase. When antigen TAGs are used, preferred embodiments utilize cell surface antigens. The epitope is preferably any detectable peptide which is not generally found on the cytoplasmic membrane, although in some instances, if the epitope is one normally found on the cells, increases may be detected, although this is generally not 15 preferred. Similarly, enzymatic detectable molecules may also be used; for example, an enzyme that generates a novel or chromogenic product. Accordingly, the results of sorting after cell phase assays generally result in at least two populations of cells that are in different cell phases. The proteins and nucleic acids provided herein can also be used for screening purposes wherein 20 the protein-protein interactions of the p1 5 PAF cell cycle proteins can be identified. Genetic systems have been described to detect protein-protein interactions. The first work was done in yeast systems, namely the "yeast two-hybrid" system. The basic system requires a protein-protein interaction in order to turn on transcription of a reporter gene. Subsequent work was done in mammalian cells. See Fields et al., Nature 340:245 (1989); Vasavada et al., PNAS USA 88:10686 25 (1991); Fearon et al., PNAS USA 89:7958 (1992); Dang et al., Mol. Cell. Biol. 11:954 (1991); Chien et al., PNAS USA 88:9578 (1991); and U.S. Patent Nos. 5,283,173, 5,667,973, 5,468,614, 5,525,490, and 5,637,463. a preferred system is described in Serial Nos. 09/050,863, filed March 30, 1998 and 09/359,081 filed July 22, 1999, entitled "Mammalian Protein Interaction Cloning System". For use in conjunction with these systems, a particularly useful shuttle vector is 30 described in Serial No. 09/133,944, filed August 14, 1998, entitled "Shuttle Vectors". In general, two nucleic acids are transformed into a cell, where one is a "bait" such as the gene encoding a p1 5 PAF cell cycle protein or a portion thereof, and the other encodes a test candidate. Only if the two expression products bind to one another will an indicator, such as a fluorescent protein, be expressed. Expression of the indicator indicates when a test candidate binds to the 35 p15PAF cell cycle protein and can be identified as an p 1 5PAF cell cycle protein. Using the same system and the identified p 15 PAF cell cycle proteins the reverse can be performed. Namely, the 38 WO 01/29072 PCT/USOO/41296 p1 5 PAF cell cycle proteins provided herein can be used to identify new baits, or agents which interact with p15PAF cell cycle proteins. Additionally, the two-hybrid system can be used wherein a test candidate is added in addition to the bait and the p1 5 PAF cell cycle protein encoding nucleic acids to determine agents which interfere with the bait, such as PCNA, and the p 15 PAF cell cycle 5 protein. In one embodiment, a mammalian two-hybrid system is preferred. Mammalian systems provide post-translational modifications of proteins which may contribute significantly to their ability to interact. In addition, a mammalian two-hybrid system can be used in a wide variety of mammalian 10 cell types to mimic the regulation, induction, processing, etc. of specific proteins within a particular cell type. For example, proteins involved in a disease state (i.e., cancer, apoptosis related disorders) could be tested in the relevant disease cells. Similarly, for testing of random proteins, assaying them under the relevant cellular conditions will give the highest positive results. Furthermore, the mammalian cells can be tested under a variety of experimental conditions that 15 may affect intracellular protein-protein interactions, such as in the presence of hormones, drugs, growth factors and cytokines, radiation, chemotherapeutics, cellular and chemical stimuli, etc., that may contribute to conditions which can effect protein-protein interactions, particularly those involved in cancer. Assays involving binding such as the two-hybrid system may take into account non-specific binding 20 proteins (NSB). Expression in various cell types, and assays for cell cycle activity are described above. The activity assays, such as having an effect on pcna binding can be performed to confirm the activity of p1 5 PAF cell cycle proteins which have already been identified by their sequence identity/similarity or binding to PCNA as well as to further confirm the activity of lead compounds identified as 25 modulators of R0101. The components provided herein for the assays provided herein may also be combined to form kits. The kits can be based on the use of the protein and/or the nucleic acid encoding the p1 5 PAF cell cycle proteins. In one embodiment, other components are provided in the kit. Such 30 components include one or more of packaging, instructions, antibodies, and labels. Additional assays such as those used in diagnostics are further described below. In this way, bioactive agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the p1 5 PAF cell cycle protein. The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a 35 host, as further described below. The present discovery relating to the role of p 15 PAF cell cycle proteins in the cell cycle thus 39 WO 01/29072 PCT/USOO/41296 provides methods for inducing or preventing cell proliferation in cells. In a preferred embodiment, the p15PAF cell cycle proteins, and particularly pl5PAF cell cycle protein fragments, are useful in the study or treatment of conditions which are mediated by the p1 5 PAF cell cycle proteins, i.e. to diagnose, treat or prevent cell cycle associated disorders. Thus, "cell cycle associated disorders" 5 or "disease state" include conditions involving both insufficient or excessive cell proliferation and preferably, cancer. As shown in the examples, p1 5 PAF is particularly associated with esophageal tumors, breast tumors, uterine tumors, ovarian cancer, brain tumors, kidney tumors and lung tumors. Thus, in one embodiment, cell cycle regulation in cells or organisms are provided. In one 10 embodiment, the methods comprise administering to a cell or individual in need thereof, a p 15 PAF cell cycle protein in a therapeutic amount. Alternatively, an anti-cell cycle antibody that reduces or eliminates the biological activity of the endogeneous p15PAF cell cycle protein is administered. In another embodiment, a bioactive agent as identified by the methods provided herein is administered. Alternatively, the methods comprise administering to a cell or individual a 15 recombinant nucleic acid encoding an p 1 5 PAF cell cycle protein. As will be appreciated by those in the art, this may be accomplished in any number of ways. In a preferred embodiment, the activity of cell cycle is increased by increasing the amount of cell cycle in the cell, for example by overexpressing the endogeneous cell cycle or by administering a gene encoding a pl 5 PAF cell cycle protein, using known gene-therapy techniques, for example. In a preferred embodiment, the 20 gene therapy techniques include the incorporation of the exogeneous gene using enhanced homologous recombination (EHR), for example as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Without being bound by theory, it appears that p1 5 PAF cell cycle protein is an important protein in the cell cycle. Accordingly, disorders based on mutant or variant pl 5 PAF cell cycle genes may be 25 determined. In one embodiment, the invention provides methods for identifying cells containing variant p1 5 PAF cell cycle genes comprising determining all or part of the sequence of at least one endogeneous cell cycle genes in a cell. As will be appreciated by those in the art, this may be done using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the cell cycle genotype of an individual comprising determining all 30 or part of the sequence of at least one cell cycle gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced cell cycle gene to a known cell cycle gene, i.e. a wild-type gene. The sequence of all or part of the cell cycle gene can then be compared to the sequence of a 35 known cell cycle gene to determine if any differences exist. This can be done using any number of known sequence identity programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the cell cycle gene of the patient and the known cell cycle 40 WO 01/29072 PCT/USOO/41296 gene is indicative of a disease state or a propensity for a disease state. In one embodiment, the invention provides methods for diagnosing a cell cycle related condition in an individual. The methods comprise measuring the activity of cell cycle in a tissue from the individual or patient, which may include a measurement of the amount or specific activity of a 5 p 15 PAF cell cycle protein. This activity is compared to the activity of cell cycle from either a unaffected second individual or from an unaffected tissue from the first individual. When these activities are different, the first individual may be at risk for a cell cycle associated disorder. In this way, for example, monitoring of various disease conditions may be done, by monitoring the levels of the protein or the expression of mRNA therefor. Similarly, expression levels may correlate to the 10 prognosis. In one aspect, the expression levels of p1 5 PAF cell cycle protein genes are determined in different patient samples or cells for which either diagnosis or prognosis information is desired. Gene expression monitoring is done on genes encoding p15PAF cell cycle proteins. In one aspect, the expression levels of p1 5 PAF cell cycle protein genes are determined for different cellular states, 15 such as normal cells and cells undergoing apoptosis or transformation. By comparing p1 5 PAF cell cycle protein gene expression levels in cells in different states, information including both up- and down-regulation of p1 5 PAF cell cycle protein genes is obtained, which can be used in a number of ways. For example, the evaluation of a particular treatment regime may be evaluated: does a chemotherapeutic drug act to improve the long-term prognosis in a particular patient. Similarly, 20 diagnosis may be done or confirmed by comparing patient samples. Furthermore, these gene expression levels allow screening of drug candidates with an eye to mimicking or altering a particular expression level. This may be done by making biochips comprising sets of important p1 5 PAF cell cycle protein genes, such as those of the present invention, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression 25 levels of the p15PAF cell cycle proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the p1 5 PAF cell cycle protein nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the p 15 PAF cell cycle proteins administered as therapeutic drugs. p1 5 PAF cell cycle protein sequences bound to biochips include both nucleic acid and amino acid 30 sequences as defined above. In a preferred embodiment, nucleic acid probes to p 1 5 PAF cell cycle protein nucleic acids (both the nucleic acid sequences having the sequences outlined in the Figures and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the p 15 PAF cell cycle protein nucleic acids, i.e. the target sequence (either the target sequence of the sample or to other probe 35 sequences, for example in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization 41 WO 01/29072 PCT/USOO/41296 between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently 5 complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein. A "nucleic acid probe" is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases 10 long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases (e.g., whole genes). As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant 15 the association or binding between the nucleic acid probe and the solid support is sufficient to be stable-under the conditions of binding, washing, analysis, and removal as outlined below. The binding can be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of either electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to 20 the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or 25 the probe or both molecules. Immobilization may also involve a combination of covalent and non covalent interactions. In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip. 30 The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant any material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or 35 functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), 42 WO 01/29072 PCT/USOO/41296 polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably show fluorescence. In a preferred embodiment, the surface of the biochip and the probe may be derivatized with 5 chemical functional groups for subsequent attachment of the two. Thus, for example, the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino 10 groups, for example using linkers as are known in the art; for example, homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200, incorporated herein by reference). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used. In this embodiment, oligonucleotides, corresponding to the nucleic acid probe, are synthesized as 15 is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside. In an additional embodiment, the immobilization to the solid support may be very strong, yet non covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces 20 covalently coated with streptavidin, resulting in attachment. Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. 25 Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChipTM technology. "Differential expression," or grammatical equivalents as used herein, refers to both qualitative as well as quantitative differences in the genes' temporal and/or cellular expression patterns within 30 and among the cells. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, for example, normal versus apoptotic cell. That is, genes may be turned on or turned off in a particular state, relative to another state. As is apparent to the skilled artisan, any comparison of two or more states can be made. Such a qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by 35 standard techniques in one such state or cell type, but is not detectable in both. Alternatively, the 43 WO 01/29072 PCT/USOO/41296 determination is quantitative in that expression is increased or decreased; that is, the expression of the gene is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by 5 use of Affymetrix GeneChip T M expression arrays, Lockhart, Nature Biotechnology 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, Northern analysis and RNase protection. As will be appreciated by those in the art, this may be done by evaluation at either the gene transcript, or the protein level; that is, the amount of gene expression may be monitored using 10 nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, for example through the use of antibodies to the p1 5 PAF cell cycle protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. 15 In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding an p15PAF cell cycle protein is detected by 20 binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate. In another preferred method, expression of p15PAF cell cycle protein is performed using in situ imaging techniques employing antibodies to p15PAF cell cycle proteins. In this method cells are contacted with from one to many antibodies to the p1 5 PAF cell cycle protein(s). Following washing 25 to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the p1 5 PAF cell cycle proteins) contains a detectable label. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in 30 simultaneous screening for a plurality of p1 5 PAF cell cycle proteins. The label may be detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in this method. As will be appreciated by one of ordinary skill in the art, numerous other histological imaging techniques are useful in the invention and the antibodies can be used in ELISA, immunoblotting (Western blotting), 35 immunoprecipitation, BIACORE technology, and the like. In one embodiment, the p15PAF cell cycle proteins of the present invention may be used to 44 WO 01/29072 PCT/USOO/41296 generate polyclonal and monoclonal antibodies to p15PAF cell cycle proteins, which are useful as described herein. Similarly, the p 15 PAF cell cycle proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify cell cycle antibodies. In a preferred embodiment, the antibodies are generated to epitopes unique to 5 the p1 5 PAF cell cycle protein; that is, the antibodies show little or no cross-reactivity to other proteins. These antibodies find use in a number of applications. For example, the cell cycle antibodies may be coupled to standard affinity chromatography columns and used to purify p1 5 PAF cell cycle proteins as further described below. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the p1 5 PAF cell cycle protein. 10 The anti-p15PAF cell cycle protein antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the p15PAF 15 cell cycle protein or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid a, 20 synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation. The anti-p15PAF cell cycle protein antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other 25 appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include the p1 5 PAF cell cycle protein or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are 30 desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. 35 Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme 45 WO 01/29072 PCT/USOO/41296 hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression 5 of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Rockville, Maryland. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal 10 antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63]. The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against p1 5 PAF cell cycle protein. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by 15 immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme linked immunosorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution 20 procedures and grown by standard methods [Goding, supral Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal. The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for 25 example, protein a-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using 30 oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of 35 monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, 46 WO 01/29072 PCT/USOO/41296 by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., supral or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for 5 the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody. The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at 10 any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking. In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine 15 techniques known in the art. The anti-p15PAF cell cycle protein antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence 20 derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human 25 residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus 30 sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)]. Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized 35 antibody has one or more amino acid residues introduced into it from a source which is non human. These non-human amino acid residues are often referred to as "import" residues, which 47 WO 01/29072 PCT/USOO/41296 are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human 5 antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. 10 Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. BioL, 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)]. 15 Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 20 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technoloqy 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al., Nature Biotechnology 4, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995). 25 Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the p 15 PAF cell cycle protein, the other one is for any other antigen, and preferably for a cell surface protein or receptor or receptor subunit. Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant 30 production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, Nature, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct 35 molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655 3659 (1991). 48 WO 01/29072 PCT/USOO/41296 Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI) containing the site 5 necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymoloqy, 121:210 (1986). 10 Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that 15 the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980. 20 The anti-p 15PAF cell cycle protein antibodies of the invention have various utilities. For example, anti-p15PAF cell cycle protein antibodies may be used in diagnostic assays for an p1 5 PAF cell cycle protein, e.g., detecting its expression in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect 25 sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: a Manual of Techniques, CRC Press, Inc. (1987) pp. 147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as 30 3 H, 14C, 32 p, 3S, or 1251, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. 35 Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982). Anti-P15PAF cell cycle protein antibodies also are useful for the affinity purification of p1 5 PAF cell cycle protein from recombinant cell culture or natural sources. In this process, the antibodies against p1 5 PAF cell cycle protein are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with 49 WO 01/29072 PCT/USOO/41296 a sample containing the p15PAF cell cycle protein to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the p1 5 PAF cell cycle protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the p 1 5 PAF cell cycle protein from the 5 antibody. The anti-p15PAF cell cycle protein antibodies may also be used in treatment. In one embodiment, the genes encoding the antibodies are provided, such that the antibodies bind to and modulate the pl 5 PAF cell cycle protein within the cell. In one embodiment, a therapeutically effective dose of an p1 5 PAF cell cycle protein, agonist or 10 antagonist is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for p1 5 PAF cell cycle protein degradation, systemic versus localized delivery, as well as the age, body weight, general health, sex, diet, time of administration, drug 15 interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals, and organisms. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, and in the most 20 preferred embodiment the patient is human. The administration of the p1 5 PAF cell cycle protein, agonist or antagonist of the present invention can be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the 25 composition may be directly applied as a solution or spray. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%. The pharmaceutical compositions of the present invention comprise an p 1 5 PAF cell cycle protein, agonist or antagonist (including antibodies and bioactive agents as described herein) in a form 30 suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric 35 acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids 50 WO 01/29072 PCT/USOO/41296 such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such 5 as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as 10 isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. Additives are well known in the art, and are used in a variety of formulations. 15 Combinations of the compositions may be administered. Moreover, the compositions may be administered in combination with other therapeutics, including growth factors or chemotherapeutics and/or radiation. Targeting agents (i.e. ligands for receptors on cancer cells) may also be combined with the compositions provided herein. In one embodiment provided herein, the antibodies are used for immunotherapy, thus, methods of 20 immunotherapy are provided. By "immunotherapy" is meant treatment of pl 5 PAF cell cycle protein related disorders with an antibody raised against a p15PAF cell cycle protein. As used herein, immunotherapy can be passive or active. Passive immunotherapy, as defined herein, is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response can be 25 the consequence of providing the recipient with an p15PAF cell cycle protein antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the p15PAF cell cycle protein antigen may be provided by injecting an p1 5 PAF cell cycle protein against which antibodies are desired to be raised into a recipient, or contacting the recipient with an p 1 5 PAF cell cycle protein nucleic acid, capable of expressing the p1 5 PAF cell cycle protein antigen, under conditions for 30 expression of the p1 5 PAF cell cycle protein antigen. In a preferred embodiment, a therapeutic compound is conjugated to an antibody, preferably an p1 5 PAF cell cycle protein antibody. The therapeutic compound may be a cytotoxic agent. In this method, targeting the cytotoxic agent to apoptotic cells or tumor tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with apoptosis, 35 cancer p1 5 PAF cell cycle protein related disorders. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable 51 WO 01/29072 PCT/USOO/41296 toxins and their corresponding fragments include diptheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against p1 5 PAF cell cycle proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the 5 antibody. In a preferred embodiment, p1 5 PAF cell cycle protein genes are administered as DNA vaccines, either single nucleic acids or combinations of p1 5 PAF cell cycle protein genes. Naked DNA vaccines are generally known in the art; see Brower, Nature Biotechnology 16:1304-1305 (1998). Methods for the use of nucleic acids as DNA vaccines are well known to one of ordinary skill in the 10 art, and include placing an p1 5 PAF cell cycle protein gene or portion of an p1 5 PAF cell cycle protein nucleic acid under the control of a promoter for expression in a patient. The p1 5 PAF cell cycle protein gene used for DNA vaccines can encode full-length p1 5 PAF cell cycle proteins, but more preferably encodes portions of the p1 5 PAF cell cycle proteins including peptides derived from the p1 5 PAF cell cycle protein. In a preferred embodiment a patient is immunized with a DNA vaccine 15 comprising a plurality of nucleotide sequences derived from a p1 5 PAF cell cycle protein gene. Similarly, it is possible to immunize a patient with a plurality of p1 5 PAF cell cycle protein genes or portions thereof, as defined herein. Without being bound by theory, following expression of the polypeptide encoded by the DNA vaccine, cytotoxic T-cells, helper T-cells and antibodies are induced which recognize and destroy or eliminate cells expressing p1 5 PAF cell cycle proteins. 20 In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the p1 5 PAF cell cycle protein encoded by the DNA vaccine. Additional or alternative adjuvants are known to those of ordinary skill in the art and find use in the invention. The examples discussed herein serve to more fully describe the manner of using the above 25 described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All references cited herein are expressly incorporated by reference in their entirety. Moreover, all sequences displayed, cited by reference or accession number in the references are incorporated by reference 30 herein. EXAMPLE pl 5 PAF was identified in a yeast two hybrid screening using PCNA as the bait. Materials and methods Yeast two-hybrid screening 52 WO 01/29072 PCT/USOO/41296 For yeast two-hybrid screening (Fields and Song, 1989), full length PCNA was used as bait to screen a human brain cDNA library constructed from mixed mRNA of whole adult brain, whole fetal brain, hippocampus, and thalamus. Oligo-dT primer was used to make a unidirectional cDNA library and was ligated into Xhol-EcoRI sites of the pACT2 vector. Random hexamer was used to 5 construct a second bi-directional library and was ligated into the EcoRI site of pACT2. The combined cDNA library represents 36 million independent clones. Yeast strain Y190 was used and 20 million transformants were screened on SD-LWH+3AT (45mM) plates from a single round of screening. Transfection and immunoprecipitation 10 The Ca' phosphate method was used in all transfection experiments. Cells were collected from 2 x 106 Phoenix-A (293 T) cells 24 hours after the transfection of HA-p1 5PAF (5 mg) and lysed in 0.5 ml lysis buffer (50mM HEPES [7.6], 250 mM NaCl, 0.1% NP-40, 5mM EDTA). The immunoprecipitated proteins were prepared by incubating the anti-HA monoclonal Ab with the cell lysates. Volumes were adjusted by normalization with expression of Flag-tagged or HA-tagged 15 proteins analyzed by Western blot analysis (protein levels before adjustment for IP shown in middle and bottom panels of Figure 2). The anti-HA immunoprecipitated samples were then washed three times with high stringency lysis buffer (1% NP-40, and 1 M NaCl). For each immunoprecipitation following normalization, aliquots of the lysates were incubated with a 1:1 slurry of anti-HA conjugated Sepharose (BAbCO). The Sepharose beads were washed once with 1 ml 20 lysis buffer and three times with high stringency lysis buffer (1 M NaCl, 1% NP-40). The immunoprecipitated proteins or cell lysates were fractionated on a 4-20% gradient SDS-PAGE gel (Novex). Co-precipitated Flag-RIP3 (proteins were detected by immunoblotting with anti-Flag polyclonal Ab. Cell cycle assay 25 A549 cells were infected with vector or p1 5 PAF retrovirus supernatant which were collected from transfected phoneix A cells. The top 10% of GFP positive A549 cells 48 hrs post infection were isolated and cell cycle analysis performed with hypotonic P1 solution staining by FCS 72 hrs post infection. The FCS data was analyzed by ModFit LT cell cycle analysis software (Verity Software House, Maine). 30 Fluorescencev GFP-fused p15PAF was transfected into 293 (Phoenix) cells. A Nikon TE-300 fluorescence microscope was used to monitor protein expression and localization in the cells. The UV excitation wavelength is between 420 and 490 nm and the GFP emission is monitored at 520 nm. Results 35 Identification of p1 5 PAF 53 WO 01/29072 PCT/USOO/41296 Large number proteins have been cloned by binding to PCNA. To clone less abundant PCNA associated proteins, we constructed a yeast two-hybrid cDNA library from mixed human tissues of adult whole brain, fetal whole brain, thalamus, and hippocampus at 1:1:1:1 ratio instead of using whole brain mRNA only. This library contains 36 million independent clones. Twenty million 5 transformants were screened. A total of seventy-three positive clones were identified, including three known PCNA binding proteins (p21, FEN-1, and Uracil-DNA glycosylase 2), validating the authenticity and efficiency of the screen. Five of the 73 PCNA-interactive clones contained cDNA insert corresponding to an expressed sequence tag (EST) clone KIAA0101 deposited in GenBank (Nagase et al, (1995). DNA Res., 2, 37-43(. KIAA0101 was conceptually translated but functionally 10 uncharacterized. Because of its PCNA-binding activity, we have therefore named KIAA0101 as PAF (PCNA associated factor). Notably, PAF contains a sequence closely related to the PCNA binding motif present in other PCNA-interacting proteins (Warbrick, 1998 supra). In particular, three highly conserved residues, GIn, Met/lle/Leu, and Phe, are all conserved in PAF, suggesting that PAF may bind to PCNA in a similar manner as other PCNA binding proteins (see below). 15 p1 5 PAF binds to PCNA in mammalian cells Conceptual translation of PAF predicts a 15 kD protein (p15PAF). We confirmed this by transient transfection and immunoprecipitation. To confirm the binding of p1 5 PAF with PCNA in mammalian cells, HA-tagged p15 PAF was cloned into a CMV promoter expression vector (pYCI) and was transfected into 293 cells. The results show that HA-tagged p1 5 PAF was able to co 20 immunoprecipitate with endogenous PCNA. Mutation of two conserved residues in the putative PCNA binding motif (165A, F68A) in the PIP-box, completely disrupted the binding of p1 5 PAF to PCNA, while both the wild type and the mutant p1 5 PAF were expressed at similar protein levels (data not shown). This result demonstrated that the PIP-box is required for p15PAF's binding to PCNA. 25 p 15 PAF competes with p21 for binding to PCNA p21 has been shown to compete with DNA polymerase and FEN-1 for binding to PCNA. Since both p1 5 PAF and p21 share the same PCNA-binding motif, it would be important to test whether p1 5 PAF can compete with p21 for binding to PCNA. HA-tagged p1 5 PAF was co-transfected with Flag-tagged p21 into 293 cells. p15PAF's binding to PCNA was diminished in the presence of increasing 30 concentration of p21. When Flag-tagged p21 was co-transfected with GFP or HA-tagged p1 5 PAF into 293 cells, p21's binding to PCNA was also inhibited by increasing the amount of p1 5 PAF Results from HA-tagged p15PAF co-transfection are not shown. Since only very high levels of p1 5 PAF (6:1 ratio) are able to compete with p21 for PCNA association, it is speculated that the affinity of p1 5 PAF to PCNA may be weaker than that p21, although endogenous levels of p21 and 35 p15PAF are not known in these transfection experiments. Tissue-specific expression and nuclear localization of PAF 54 WO 01/29072 PCT/USOO/41296 PAF gene was expressed as a 1.1 kb message that accumulates in liver, pancreas, and placenta at a high level (data not shown). PAF expression was not detected in heart or whole adult brain, despite the initial isolation from a brain cDNA library. To determine the subcellular localization, we fused full length PAF to the C-terminal of GFP and expressed PAF-GFP protein in Hela cells by 5 transient transfection. The results (not shown) indicate that the majority of green fluorescence was observed in the nucleus, although some cytoplasmic distribution can also be seen. Hence, PAF is mainly localized in the nucleus. p 15 PAF expression is increased in tumor tissues PCNA expression has been correlated to tumor progression and is commonly used as a molecular 10 marker for detecting hyperplastic cell growth. Greater p21 expression has also been seen in certain types of malignant tumors (Baekelandt et al., (1999). Clin Cancer Res., 5, 2848-2853; Barboule et al, (1998). Int J Cancer, 76, 891-896). Some cancer patients with higher level of p 2 1 expression also had higher 5-year survival rates (Kuwahara et al.,(1999). Dis Esophagus., 12, 116 119; Natsugoe et al., (1999). Clin Cancer Res., 5, 2445-2449; Ropponen et al, (1999). Br. J. 15 Cancer, 81, 133-140). To evaluate pl 5 PAF,S potential function in tumor development, pl 5 PAF expression level was measured using tumor blots (Invitrogen). The p1 5 PAF mRNA level was significantly increased in esophageal tumor, breast tumor, uterine tumor, ovarian cancer, brain tumor, kidney tumor, and lung tumor. This increased mRNA level is especially dramatic for esophageal tumor (10 fold). Northern analysis also verified that in normal whole adult brain tissue, 20 little or no p1 5 PAF was detected. Little or a non-detectable change of p1 5 PAF expression was observed in colorectal cancer or pancreas tumor. Discussion Both PCNA and p21 have been shown to interact with a large number of cellular proteins involved in DNA replication/repair and cell cycle control. Most of the non-enzymatic PCNA binding proteins 25 identified, such as p21 and p57, inhibit DNA synthesis and cell cycle progression. Since p 15 PAF is able to compete with p21 for binding to PCNA, it is plausible to speculate that over-expression of p 15 PAF in tumor tissues may be advantageous for tumor cell proliferation. However, co-transfection of p1 5 PAF with p21 expression plasmid into Saos-2 and 293 cells did not show significant change in p21 induced cell cycle arrest. In addition, PCNA has more than one p21/ p 1 5 PAF binding site and 30 may bind to both pl 5 PAF and p21 at the same time. Without knowing the relative endogenous protein level of p1 5 PAF and p21, it is difficult to determine the relative relationship between p1 5 PAF and p21. Under physiological conditions, p1 5 PAF may not be able to compete with p21 for PCNA binding. p21 binds to PCNA to disrupt DNA replication/repair machinery and to inhibit cell proliferation. However, in transient transfection experiments using Hela, Saos-2, and 293 cells, we 35 were not able to detect any cell cycle inhibition by the overexpression of p1 5 PAF (data not shown). In vitro DNA synthesis assay may be needed to reveal the detailed mechanism of p1 5 PAF function. 55 WO 01/29072 PCT/USOO/41296 Since p1 5 PAF's mRNA level is dramatically increased in many types of tumors, we sequenced RT PCR amplified p 15 PAF from kidney tumor, liver tumor, lung tumor, and esophageal tumor. No mutation was found in p1 5 PAF (data not shown). This result excludes the possibility that a dysfunctional copy of p1 5 PAF is over-expressed in tumor tissues. Increased expression of p1 5 PAF in 5 many tumor tissues is not surprising. Expression of PCNA and PCNA-associated proteins such as p21 is also increased in several type of cancers including ovarian cancer and breast cancer. The inhibitory effect of p21 may be overcome by coordinated accumulation of PCNA, cyclinD1, and CDKs (Russell et al., 1999 Oncogene, 18, 6454-6459). Similarly, the impact of increased expression of p1 5 PAF in tumor tissues may be neutralized by elevated expression of its binding 10 partners, such as PCNA. However, elevated level of p1 5 PAF in tumor tissues is a useful prognostic parameter for certain types of cancer. In esophageal squamous cell carcinoma patients, for example, the 5-year survival rate of p21 positive patients is better than that of p21 negative patients. Since p15PAF expression in esophageal tumor is dramatically elevated compared with normal tissue, p1 5 PAF levels can be also used to estimate the prognosis for esophageal cancer 15 patients. 56

Claims

1. A method for screening for a bioactive agent capable of binding to a p1 5 PAF cell cycle protein R0101, said method comprising: 5 a) combining a p 1 5 PAF cell cycle protein R0101 and a candidate bioactive agent; and b) determining the binding of said candidate bioactive agent to said p1 5 PAF cell cycle protein R0101.

2. A method for screening for a bioactive agent capable of interfering with the binding of a p1 5 PAF cell cycle protein R0101 and a PCNA protein, said method comprising: 10 a) combining a pl 5 PAF cell cycle protein R0101, a candidate bioactive agent and a PCNA protein; and b) determining the binding of said p1 5 PAF cell cycle protein R0101 and said PCNA protein.

3. A method according to Claim 2, wherein said p 15 PAF cell cycle protein R0101 and said PCNA protein are combined first. 15

4. A method for screening for a bioactive agent capable of modulating the activity of p1

5 PAF cell cycle protein R0101, said method comprising: a) adding a candidate bioactive agent to a cell comprising a recombinant nucleic acid encoding a p1 5 PAF cell cycle protein R0101; and b) determining the effect of said candidate bioactive agent on said cell. 20 5. A method according to Claim 4, wherein a library of candidate bioactive agents is added to a plurality of cells comprising a recombinant nucleic acid encoding a p1 5 PAF cell cycle protein R0101.

6. An antibody to a p1 5 PAF cell cycle protein.

7. The antibody of Claim 6 wherein said antibody is a monoclonal antibody. 25

8. The antibody of Claim 6 wherein said antibody reduces or eliminates the biological function of said p1 5 PAF cell cycle protein.

9. A method of diagnosing cancer in an individual, said method comprising determining the level of expression of R0101 in a sample taken from an individual and comparing said level to a control which has a level which indicates there is no cancer, wherein an increase in said sample 30 compared to said control indicates a diagnoses of cancer. 57